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Leveraging genomic approaches to characterize 
mitochondrial RNA biology 
 
Abstract 
 
Transcription and translation of mammalian mitochondrial DNA (mtDNA) occurs 
within the mitochondrial matrix to produce oxidative phosphorylation subunits required 
for efficient energy production. These mtDNA-encoded subunits complex with 
mitochondrial-localized, nuclear-encoded subunits to form the respiratory chain, and 
aberrant production or function of these subunits can cause devastating human disease. 
In addition to 13 oxidative phosphorylation subunits, mtDNA encodes 2 rRNAs and 22 
tRNAs. All proteins required for mitochondrial RNA transcription, processing, and 
translation are encoded in the nucleus and translocated into the mitochondria. Here, I 
characterize over 100 nuclear-encoded mitochondrial proteins with predicted RNA-
binding domains. Using RNAi and an RNA profiling approach, MitoString, we further 
characterize previously identified RNA processing factors and identify the novel 
regulator FASTKD4, which influences the abundance of a subset of mitochondrial 
mRNAs. Next, we apply knowledge of the RNA degradation component SUPV3L1 
gleaned from our RNAi studies and previous research to test whether a specific set of 
variants influence the function of this gene in patient fibroblasts. Using MitoString, we 
find no evidence of pathogenicity of these variants in our fibroblast model. Our approach 
highlights the value of a thorough understanding of mitochondrial proteins and the 
iv 
necessity of experimental techniques to validate the effect of variants found in exome-
sequencing studies. Finally, we take an unbiased approach to characterizing the 
mitochondrial transcriptome of mouse liver by sequencing RNA from sequentially 
enriched mitochondrial fractions. Although we find an abundance of nuclear-encoded 5S 
rRNA, consistent with previous research, we fail to identify any imported nuclear-
encoded tRNAs. Uniting genomics, biochemistry, and medicine, these findings advance 
our understanding of mitochondrial RNA biology. 
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  Chapter 1 
Introduction  
 
Overview 
 Over 1.5 billion years ago, the mitochondrion’s prokaryotic ancestor invaded the 
proto-eukaryotic cell, ushering in DNA encoding rRNAs, tRNAs, and mRNAs necessary 
for the energy-generating process we know as oxidative phosphorylation (Sicheritz-
Pontén et al., 1998). As oxidative phosphorylation (OXPHOS) became indispensible to 
its host and the mitochondrion lost autonomy, many of these genes transferred to the 
nuclear genome and were lost from mitochondrial DNA (mtDNA). In mammalian 
mitochondria, 13 essential subunits of the respiratory chain remain encoded by mtDNA 
(Anderson et al., 1981) (Figure 1-1). These mtDNA-encoded genes require nuclear-
encoded proteins, of both prokaryotic ancestry and eukaryotic innovation, for their 
transcription, processing, and translation. Without proper production of these mtDNA-
encoded subunits, OXPHOS malfunctions, triggering devastating human diseases. 
OXPHOS is the process by which mitochondria synthesize ATP by harvesting the 
energy from a proton gradient formed by electron transfer through the respiratory chain. 
Complexes I-IV couple electron transfer to oxygen with formation of a proton gradient, 
which then powers ATP production by ATP synthase (Complex V). Excepting Complex 
II, each of these complexes is composed of proteins encoded by both the nuclear and 
mitochondrial genomes. Nuclear proteins are translocated into the mitochondria, while 
the mtDNA transcripts are translated by mitochondrial ribosomes within the 
mitochondrial matrix. 
	    
Figure 1-1. Human mtDNA encodes 13 proteins, 22 tRNAs, and 2 rRNAs  
The 16.5 kB compact circular mitochondrial genome is shown with rRNAs depicted in 
blue, mRNAs in purple, and tRNAs in grey (labeled by their 1 letter abbreviations). The 
genome is transcribed from three promoters: LSP (light strand promoter) initiates 
transcription of ND6 and the light strand tRNAs; HSP1 (heavy strand promoter 1) 
transcribes the two rRNAs and the phenylalanine and valine tRNAs; and HSP2 (heavy 
strand promoter 2) initiates within the phenylalanine tRNA and transcribes the 
remainder of the heavy strand. 
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  In addition to OXPHOS subunits, roughly 1,100 nuclear-encoded proteins are 
mitochondrial-localized; the identity of these proteins has been collated into a list termed 
MitoCarta (Pagliarini et al., 2008). Among these translocated proteins are metabolic 
enzymes, components of the mtDNA nucleoid, and various RNA processing proteins. 
The MitoCarta compendium is particularly powerful for prioritized screening applications. 
When seeking to identify an unknown protein that enables a particular mitochondrial 
function, starting with MitoCarta immediately narrows the search space. This approach 
has enabled identification of components of the mitochondrial calcium uniporter 
(Baughman et al., 2011; Perocchi et al., 2010), and in Chapter 2 enables the 
identification of a new regulator of mitochondrial RNAs, FASTKD4. Additionally, 
MitoCarta has enabled prioritization of candidate genes for molecular diagnosis of 
mitochondrial disorders caused by nuclear mutations (Calvo et al., 2012; Lieber et al., 
2013). However, these variants cannot be proven pathogenic without molecular proof, 
and in Chapter 3 I describe an approach to tackle this challenge using a mitochondrial 
RNA profiling technique developed in Chapter 2. In Chapter 4, I use sequential 
enrichment of mitochondria to determine whether any nuclear RNA transcripts are 
imported into mitochondria along with MitoCarta proteins. 
Why does mtDNA persist? 
 If so many historically mitochondrial genes have been successfully transitioned to 
the nucleus, why do any remain encoded in mtDNA? Three theories have been posed 
to answer this question. First, the proteins that remain encoded by mtDNA are 
extremely hydrophobic, and their efficient translocation into mitochondria may be 
3
	  inhibited by this property, as only unfolded proteins can be translocated (Popot and de 
Vitry, 1990). Second, the mtDNA genetic code is slightly different than the nuclear 
genetic code, and may prevent efficient transfer to the nucleus; in particular, a nuclear 
stop codon encodes tryptophan within the organelle (Jacobs, 1991). Finally, others have 
argued that local control of mtDNA allows rapid response of gene expression to local 
metabolic changes, known as Co-location for redox regulation (CORR) (Allen, 1993). 
These theories are not mutually exclusive, and highlight the unique nature of the 
remaining mtDNA-encoded proteins. 
mtDNA is transcribed in long polycistrons and cleaved into individual transcripts 
MtDNA is transcribed in long polycistronic units by mitochondrial RNA 
polymerase (POLRMT), which is distantly related to the polymerase from bacteriophage 
T7. Transcription initiates from three distinct promoters: light strand promoter (LSP), 
which encodes the mRNA ND6 and 8 tRNAs, and two heavy strand promoters (HSP1 
and HSP2) (Figure 1-1) (Chang and Clayton, 1984; Montoya et al., 1982). HSP1 
transcribes the two rRNA units and the first two tRNAs, while HSP2 transcribes the 
remainder of the heavy strand, producing 2 rRNAs, 10 mRNAs and 13 tRNAs (Montoya 
et al., 1983). The mRNAs ATP6/8 and ND4/4L are bicistroinc, each containing two 
overlapping reading frames. The transcription factors TFAM and TFB2M are required for 
transcription from LSP and HSP1 in vitro (Litonin et al., 2010) (Figure 1-2). 
These multigenic precursor strands are cleaved into individual rRNAs, tRNAs, 
and mRNAs. The secondary structure of the tRNAs, which intersperse the mRNAs, is 
thought to guide cleavage (Ojala et al., 1981). RNase P cleaves at the 5’ end of most 
4
	  tRNAs, while RNase Z (ELAC2) cleaves at the 3’ end (Figure 1-2) (Brzezniak et al., 
2011; Rossmanith and Karwan, 1998). Mitochondrial RNase P is a complex of three 
proteins: mitochondrial RNase P protein (MRPP) 1, MRPP2, and MRPP3 (Holzmann et 
al., 2008). In addition to this identified protein complex, a mitochondrial RNase P RNA 
has been identified with 5’ cleavage activity (Puranam and Attardi, 2001). 
 
Figure 1-2. Mitochondrial RNA processing 
Mitochondrial RNAs are transcribed in long precursor strands, known as the heavy and 
light strands, which are cleaved by RNase Z and P into individual rRNAs, tRNAs, and 
mRNAs. These transcripts are further modified and can contribute to translation, be 
degraded, or stabilized. LRPPRC and SLIRP form a complex that stabilizes mRNAs and 
has been also implicated in polyadenylation and abundance of the precursors. 
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  However, some junctions do not appear to behave as expected under knockdown of 
RNase P or Z (Lopez Sanchez et al., 2011).  
All mRNAs in mitochondria are 3’ polyadenylated with a 40-60 nucleotide tail. For 
some transcripts, the genome has been so compacted that polyadenylation is 
necessary to complete a stop codon (Temperley et al., 2010). Knockdown experiments 
have verified the role of mitochondrial poly(A) polymerase (MTPAP) in 3’ adenylation, 
however in these reports a ~10 nucleotide poly(A) tail remains, leading some to 
hypothesize that an additional polymerase is involved in the primary addition of 
adenosines, with MTPAP playing a role in extension of the poly(A) tail (Slomovic et al., 
2005; Slomovic and Schuster, 2008). Knockdown of MTPAP affects the stability of 
some, but not all of the mitochondrial mRNAs, and severely compromises mitochondrial 
membrane potential and oxygen consumption. Furthermore, MTPAP does not contain 
an RNA-binding domain, and is expected to cooperate with an unidentified partner in 
order to bind RNA (Bobrowicz et al., 2008). Internal poly(A) sites have also been 
identified, suggesting that this polyadenylation may be part of a degradation pathway 
(Slomovic et al., 2005). However, it is unclear how the two poly(A) signals are 
differentiated and which enzymes are responsible for the internal cleavage and 
subsequent polyadenylation. 
LRPPRC, SLIRP, and GRSF1 have important but murky roles in mitochondrial 
RNA regulation  
The LRPPRC-SLIRP complex is essential for mitochondrial mRNA abundance 
and sediments with a subset of mitochondrial mRNAs when separated by a density 
6
	  gradient (Ruzzenente et al., 2012). However, the exact molecular role remains 
contested. Leucine-rich PPR-motif containing protein (LRPPRC) binds mitochondrial 
polyadenylated RNAs in vivo and may play a role in nuclear RNA processing (Mili and 
Piñol-Roma, 2003). LRPPRC contains the pentatricopeptide repeat (PPR) RNA-binding 
motif, which is prevalent in hundreds of proteins active in plant organelle RNA 
processing, but is only present in five mammalian proteins, all of which are 
mitochondrial-targeted (Lightowlers and Chrzanowska-Lightowlers, 2008). SLIRP is 
found in complex with LRPPRC, and its depletion results in decreased RNA transcript 
levels and oxygen consumption (Baughman et al., 2009; Sasarman et al., 2010). 
LRPPRC has been linked to the transcription, polyadenylation, translation and 
degradation of mitochondrial mRNAs (Chujo et al., 2012; Gohil et al., 2010; Ruzzenente 
et al., 2012; Sasarman et al., 2010; Xu et al., 2004). How one protein can play so many 
roles has yet to be established, but it has been hypothesized that the mitochondrial 
precursor is coated with the LRPPRC-SLIRP complex from a very early stage and 
continues to chaperone the mRNAs through polyadenylation, translation and 
degradation (Chujo et al., 2012; Ruzzenente et al., 2012). Recently it has been 
suggested that mRNAs with longer half-lives are more affected by knockdowns of these 
proteins, but the correlation is imperfect (Chujo et al., 2012; Ruzzenente et al., 2012).  
Recent studies have found a role for GRSF1 in regulation of mitochondrial RNAs. 
GRSF1 localizes to RNA granules, punctate loci within the mitochondrial matrix, 
alongside RNase P, and is required for precursor cleavage (Jourdain et al., 2013), and it 
preferentially associates with light strand transcripts (Antonicka et al., 2013). GRSF1 
7
	  depletion also depleted rRNAs and some mRNAs and impaired ribosomal assembly 
(Antonicka et al., 2013; Jourdain et al., 2013) 
Mitochondrial RNA translation and degradation 
Each mitochondrial mRNA is translated by the mitochondrial ribosome, which is 
composed of the two mtDNA-encoded rRNAs and a number of nuclear-encoded 
proteins. The mitochondrial mRNAs were initially believed to be translated with just 22 
mitochondrial-encoded tRNAs, employing a slightly modified coding language that 
makes generous use of the wobble base (Crick, 1966). These tRNAs are excised from 
the precursor as described above, and modified by enzymes including TRNT1, which 
adds a CCA to the end of each tRNA (Nagaike et al., 2001). 
E. coli and yeast mitochondria contain nonhomologous protein complexes termed 
degradosomes for destroying RNA (Carpousis, 2007; Malecki et al., 2007). Human 
mitochondria contain homologs of degradosome components including polynucleotide 
phosphorylase (PNPase encoded by PNPT1) (E. coli ) and the helicase SUPV3L1 
(yeast); these human proteins have recently been found to form a complex in vitro 
(Wang et al., 2009). Further, knockdowns of both SUPV3L1 and PNPT1 disrupt 
mitochondrial function (Khidr et al., 2008; Slomovic and Schuster, 2008). However, 
PNPase is located in the intermembrane space, which has led to the hypothesis that it 
affects degradation of poly(A) tails through indirect means such as altering free 
nucleotide levels (Slomovic and Schuster, 2008). No other proteins have been 
implicated in degradation thus far, but the unclear roles of SUV3 and PNPase suggest 
that other proteins may be involved. 
8
	  Import of nuclear RNAs into the mitochondria 
Interestingly, PNPase is also required for import of nuclear RNAs into 
mitochondria (Wang et al., 2010). Mitochondrial import has been described for 5S rRNA, 
which associates with the mitochondrial ribosome, MRP RNA, which couples with a 
protein component to cleave RNA primers required for DNA synthesis, and RNase P 
RNA, described above (Li et al., 1994; Puranam and Attardi, 2001; Smirnov et al., 2011; 
Yoshionari et al., 1994). PNPase was found to stimulate import of both the MRP and 
RNase P RNAs, and 5S import has been biochemically characterized to require a 
specific RNA sequence and multiple cytoplasmic proteins (Smirnov et al., 2010; 
Smirnov et al., 2011; Smirnov et al., 2008; Wang et al., 2010). Although the 22 tRNAs 
present in the human mitochondria are sufficient to decode the mitochondrial genome 
with wobble of the third anticodon base, nuclear tRNAs have recently been identified 
within the mitochondria (Chomyn and Attardi, 2009; Mercer et al., 2011; Rubio et al., 
2008). The purpose and necessity of these RNAs remains unclear, and in Chapter 4, we 
describe our approach to identify and study these nuclear-encoded mitochondrial-
imported RNAs using an unbiased approach.  
Mutations in genes required for mitochondrial RNA processing cause hereditary 
mitochondrial disorders  
Inherited disorders affecting mitochondrial function can be caused by mutations 
in both mtDNA and the nuclear genome. These disorders can have diverse 
presentation, but usually affect multiple organ systems, including the nervous system, 
musculoskeletal system, and gastrointestinal tract (reviewed in Vafai and Mootha, 
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  2012). These disorders can present in patients from infancy to adulthood and range in 
severity from mild to lethal. 
Mitochondrial disorders can result from a malfunctioning respiratory chain due to 
a plethora of causes (Calvo and Mootha, 2010). Most directly, mutations in proteins that 
are subunits of the respiratory chain or chaperone proteins required for proper OXPHOS 
function can impact respiratory chain function. Mutations in proteins required for mtDNA 
maintenance and protein translation can also result in decreased OXPHOS function by 
impacting production of mtDNA-encoded respiratory chain subunits. Proteins 
responsible for RNA processing and abundance have also been implicated. 
In 2003, mutations in LRPPRC were identified as a cause of Leigh Syndrome, 
French Canadian type (LSFC), a severe infantile disorder characterized by 
neurodegeneration and severe episodes of metabolic acidosis (Mootha et al., 2003). 
LSFC patients had low cytochrome c oxidase activity, but even after identification of 
causal mutations in LRPPRC, the exact role of the protein remained unclear. 
Subsequent studies, described above, have shown that LRPPRC plays a role in 
regulation of mitochondrial RNAs, characterizing it as the first mitochondrial disease 
gene affecting mitochondrial RNAs (Gohil et al., 2010; Sasarman et al., 2010). 
 Subsequently, disease-causing mutations have been found in genes encoding 
the RNA processing factors mitochondrial poly-A polymerase (MTPAP) (Crosby et al., 
2010) and RNase Z (ELAC2) (Haack et al., 2013). Defects in MTPAP were found in an 
Amish family with several siblings affected by slowly progressive neurodegenerative 
condition marked by cerebellar ataxia, spastic lower limb movements, dysarthria 
10
	  (difficulty speaking), optic atrophy and impaired learning. In the affected siblings, but not 
the parents, improper polyadenylation of mitochondrial RNAs was observed, confirming 
that suspected variants in MTPAP cause a dysregulation of mitochondrial RNA 
processing, and likely the disease observed. ELAC2 mutations were identified in 
unrelated individuals with infantile hypertrophic cardiomyopathy, lactic acidosis, and 
isolated complex I deficiency in skeletal muscle (Haack et al., 2013). In this case, 
measurement of precursor RNAs by qPCR and RNA-sequencing identified aberrantly 
increased precursor RNAs in the affected individuals, suggesting that the ELAC2 
mutations are causal.  
Although exome-sequencing has become widespread for many inherited 
disorders, proving pathogenicity of identified variants of unknown significance is a 
challenge. Recently, Chakravarti et al. proposed a version of Koch’s postulates for 
complex human disease, including sporadic monogenic cases. The authors require 
proof at two levels: demonstration that a mutant allele causes a phenotype in a model 
system and demonstration that the model phenotype is equivalent to the human 
disease, using four crisp postulates (Chakravarti et al., 2013). For both the MTPAP and 
ELAC2 cases, an understanding of the biology of these enzymes enabled determination 
of the likely pathogenicity of the identified variants using experimental techniques. With 
the benefit of Mendelian inheritance patterns, experimental proof was less necessary. 
However, noting how each falls short of the rigorous standards proposed by Chakravarti 
et al. highlights the challenges of meeting this high standard of proof. Both papers use 
family history to prove the enrichment of mutant alleles within patients (Postulate 1) and 
11
	  fibroblast models to demonstrate a phenotype associated with disrupted gene function 
(Postulate 2). However, only in the ELAC2 case do the authors reintroduce the wild type 
allele (Postulate 3), and neither case re-introduces the mutant allele (Postulate 4). 
Following these principles, in Chapter 3 we attempt to develop a model in fibroblasts for 
a patient with candidate variants in a gene encoding a component of the mitochondrial 
RNA degradation machinery, SUPV3L1. We were aided in our approach by the body of 
knowledge surrounding this protein and a known function, described above, but still 
faced a formidable challenge. For genes that are less well characterized, developing a 
model system will be even more challenging. 
In a recent MitoExome sequencing study, molecular diagnoses were established 
for just 22% of suspected mitochondrial disease patients, while variants of unknown 
significance were prioritized for an additional 26% (Lieber et al., 2013). For many of 
these variants of unknown significance, the tools to develop and assess an appropriate 
model system are lacking. This emphasizes both the necessity of understanding the 
roles various mitochondrial enzymes play, as well as the need for molecular techniques 
that can probe the function of specific enzymes. Towards this effort, in Chapter 2 I 
develop a molecular tool for probing mitochondrial RNA expression and characterize 
over 100 mitochondrial proteins, including 13 known disease genes. 
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Summary 
Both strands of human mitochondrial DNA (mtDNA) are transcribed in continuous, 
multi-genic units that are cleaved into the mature rRNAs, tRNAs, and mRNAs required 
for respiratory chain biogenesis. We sought to systematically identify nuclear-encoded 
proteins that contribute to processing of mitochondrial RNAs (mt-RNAs) within the 
organelle. First, we devised and validated a multiplex “MitoString” assay that quantitates 
27 mature and precursor mtDNA transcripts. Second, we applied MitoString profiling to 
evaluate the impact of silencing each of 107 mitochondrial-localized, predicted RNA-
binding proteins. With the resulting dataset, we rediscover the roles of recently identified 
RNA processing enzymes, detect unanticipated roles of known disease genes in RNA 
processing, and identify new regulatory factors. We demonstrate that one such factor, 
FASTKD4, modulates half-lives of a subset of mt-mRNAs and associates with 
mitochondrial RNAs in vivo. MitoString profiling may be useful in diagnosing and 
deciphering the pathogenesis of mtDNA disorders.  
 
 
 Introduction 
Human mitochondrial DNA (mtDNA) encodes 13 protein subunits of the 
respiratory chain, as well as the 2 rRNAs and 22 tRNAs required for their translation. All 
protein factors required for mtDNA replication, transcription, and translation are nuclear-
encoded and imported into the mitochondrion. Mutations in either nuclear- or 
mitochondrial-encoded genes cause a range of heritable disorders with overlapping 
phenotypes. Expression of nuclear and mtDNA-encoded oxidative phosphorylation 
(OXPHOS) complex proteins is coordinated by nuclear transcription factors and co-
activators (Scarpulla et al., 2012). However, local control of mtDNA expression is also 
possible, as suggested by by the finding that chemical perturbations are capable of 
decoupling the expression of the two genomes (Wagner et al., 2008). 
The 16.5 kB human mitochondrial genome is highly compact and transcribed by 
mitochondrial RNA polymerase as two continuous polycistrons, one for each strand. 
The “heavy strand” expresses 2 rRNAs, 14 tRNAs and 12 mRNAs, while the “light 
strand” expresses the ND6 mRNA and 8 tRNAs (Figure 2-1AB). These precursor RNAs 
primarily contain mt-mRNAs “punctuated” by tRNAs, whose structure is proposed to 
guide the cleavage responsible for liberating individual mt-mRNAs and tRNAs 
(Anderson et al., 1981; Ojala et al., 1981). Cleavage at the 5’ end of tRNAs is catalyzed 
by the RNase P complex, which is comprised of three recently identified proteins: 
mitochondrial RNase P protein 1 (MRPP1), MRPP2, and MRPP3 (Holzmann et al., 
2008). An alternative RNase P containing an imported catalytic RNA has also been 
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 described (Puranam and Attardi, 2001). Cleavage at the 3’ end of tRNAs is catalyzed by 
the nuclease ELAC2 (Brzezniak et al., 2011; Lopez Sanchez et al.,  
 
 
Figure 2-1. MitoString screen for regulators of mitochondrial RNA processing 
(A) Schematic depicting mtDNA transcription (in two continuous units, the heavy and 
light strands), followed by cleavage into individual mRNAs, tRNAs, and rRNAs. Pink and 
turquoise lines represent MitoString probes targeting mRNAs and junctions, respectively. 
(B) Location of MitoString probes on the mtDNA heavy and light strands. rRNAs and 
mRNAs encoded by the mtDNA are labeled in white text. tRNAs are demarcated by 
their one letter symbols. The location of mRNA probes are noted in pink, junction probes 
in turquoise, and noncoding probes in grey. Rectangles indicate probes targeting the 
heavy strand, while triangles indicate probes targeting the light strand. (C) Comparison 
of the effects of shLRPPRC and shSLIRP on MitoString probes, shown as log2(fold-
change) with respect to shGFP. Probe colors and shapes are depicted as in (B). (D) 
Overview of MitoString screening approach. Candidates for lentiviral knockdown were 
selected by identifying MitoCarta proteins containing RNA-binding domains. Candidate 
genes were knocked down in WI-38 fibroblasts and the mitochondrial RNA levels were 
assessed six days later by the MitoString probes described in (B).  
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 2011). After cleavage, the mitochondrial RNA poly-A polymerase (MTPAP) 
polyadenylates the mt-mRNAs (Nagao et al., 2008; Piechota et al., 2006). Mt-mRNA 
abundance is regulated by the SLIRP- LRPPRC complex, although the exact 
mechanism is debated. LRPPRC has been implicated in mt-mRNA transcription,  
polyadenylation, translation and degradation suppression (Baughman et al., 2009; 
Chujo et al., 2012; Gohil et al., 2010; Liu et al., 2011; Ruzzenente et al., 2012; 
Sasarman et al., 2010). 
Despite the concurrent transcription of heavy strand genes, their cognate mt-
mRNAs reach distinct steady-state levels. These ten transcripts have distinct half-lives 
that fall into two categories: short-lived and long-lived. The complex I transcripts ND1–
ND3 and ND5, and the complex III transcript CYTB are short-lived (t1/2 = 68–94 min), 
whereas the complex IV transcripts cytochrome c oxidase 1 (COX1), COX2, and COX3; 
complex V bicistronic transcript ATP6/8, and complex I bicistronic transcript ND4/4L are 
long-lived (t1/2= 138-231 min) (Nagao et al., 2008). These differential mt-mRNA 
stabilities are consistent with early observations (Gelfand and Attardi, 1981) and recent 
RNA sequencing analysis (Mercer et al., 2011), but remain unexplained by transcript 
length, polyadenylation, known degradation pathways, or characterized stability factors. 
Although the purpose of these differential half-lives is unexplored, we note that 
concentrations of OXPHOS protein complexes (reviewed by Lenaz and Genova, 2010) 
tend to correlate with reported mt-mRNA half-lives (Nagao et al., 2008). Complex I is the 
least abundant complex and contains subunits encoded by the short-lived mt-mRNAs. 
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 Thus, differences in mt-mRNA abundance may help establish OXPHOS protein 
stoichiometry. 
Because all mt-mRNA transcripts but one originate from a single heavy strand 
promoter, the observed steady-state levels are expected to be highly dependent on 
transcript degradation rates (Chujo et al., 2012). The helicase SUPV3L1, in complex 
with polynucleotide phosphorylase (PNPT1), has been implicated in the degradation of 
the light-strand transcripts, and a dominant negative form of either gene stabilizes light 
strand noncoding transcripts and some short-lived heavy strand mt-mRNAs (Borowski 
et al., 2013; Szczesny et al., 2010). However, both RNAi and dominant negative 
experiments targeting SUPV3L1 or PNPT1 actually decrease levels of the long-lived mt-
mRNA COX1, indicating additional degradation or feedback mechanisms may exist. 
Our goal was to systematically identify mitochondrial proteins that contribute to 
mitochondrial RNA processing. We begin with a scalable, accurate method to measure 
multiple mitochondrial RNAs throughout the processing stages. Past approaches to 
measuring mitochondrial RNA levels, such as Northern blots, quantitative PCR, and GE-
HTS (Wagner et al., 2008), have been valuable, but limited by scalability, strand 
specificity, or dynamic range, respectively. Here, we report simultaneous, strand-
specific measurement of multiple precursor and mature mtDNA-encoded RNAs 
following stable genetic silencing of nuclear factors predicted to play a role in 
mitochondrial RNA biology. We produce a focused compendium of mitochondrial RNA 
expression across a set of targeted genetic perturbations, which we mine to probe the 
identity and role of nuclear-encoded factors in mitochondrial RNA processing. In the 
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 process, we identify FASTKD4, a novel factor that regulates the stability of a subset of 
mt-mRNAs. 
Results 
MitoString: a multiplexed assay for precursor and mature mt-RNAs 
We developed a “MitoString” assay to interrogate four types of transcripts using 
the nCounter Analysis System (Geiss et al., 2008), in which fluorescent RNA probes 
quantitate unamplified RNA within a crude cell lysate sample. First, we designed a 
probe targeting each of the highly abundant mt-mRNA transcripts (Figure 2-1B), 
achieving a coefficient of variation (CV) of 7-14% for all but one probe across 10 
independent infections of the control hairpin shGFP (Figure 2-S1AB). Second, we 
designed probes to two regions of the light strand precursor that are transcribed, but are 
not believed to encode a functional protein. Third, we designed probes overlapping the 
junctions of two adjacent genes. These junction probes only produce signal when bound 
to the unprocessed precursor transcript. Probes assessing the precursor strands have 
lower signal at baseline, and are thus noisier (Figure 2-S1C), but their levels can be 
reproducibly induced in response to perturbation. In addition, we designed probes to 
detect nuclear-encoded genes important to mitochondrial function, as well as the 
nuclear-encoded candidate genes, with the vast majority having a CV of <20% (Figure 
2-S1D).  
To verify that mtRNA perturbations are reliably measured, we profiled cells 
following transduction with PGC-1α, which induces mitochondrial biogenesis, and 
shLRPPRC, which depletes mtRNAs. PGC-1α overexpression increases mature and 
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 immature transcripts (Figure 2-S2AB), as well as nuclear-encoded, mitochondrial-
localized transcripts (Figure 2-S2C), as expected. LRPPRC silencing depletes heavy 
strand mt-mRNAs as found previously (Figure 2-1C). We further note that knockdowns 
of the individual components of the LRPPRC-SLIRP complex have well-correlated 
effects on all transcripts measured by MitoString (Figure 2-1C), suggesting that 
hierarchical clustering of MitoString profiles may be valuable for predicting gene function.  
Prioritizing candidate mt-RNA binding proteins for knockdown 
With a facile assay for quantifying immature and mature mitochondrial transcripts 
in hand, we proceeded to select genes that might be involved in mitochondrial RNA 
processing for RNAi-based silencing. We focused on members of MitoCarta, a high-
confidence collection of mitochondrial-localized proteins (Pagliarini et al., 2008), and 
prioritized proteins with known or predicted RNA-binding domains, based on Pfam, GO 
annotation, or manual curation (Figure 2-1D) (Finn et al., 2008). We excluded 
components of the mitochondrial ribosome and in total prioritized 107 candidates. 
For each of these genes, we selected the three most effective lentiviral short 
hairpin RNAs (shRNAs) available from the RNAi Consortium (Table 2-S1) (Methods). 
We screened WI-38 fetal lung fibroblasts, which are untransformed and viable after six 
days of strong LRPPRC knockdown. Cells were infected with hairpins in duplicate, and 
lysed for MitoString analysis after six days of antibiotic selection. Using our nuclear 
NanoString probes, we were able to measure knockdown efficiency for most hairpins 
within the same assay (Table 2-S2). On each 96-well screening plate, we included five 
hairpins targeting non-human sequences as RNAi controls, a hairpin targeting LRPPRC 
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 known to deplete mt-mRNAs (Figure 2-1C), and a PGC-1α overexpression construct to 
stimulate mitochondrial biogenesis (Figure 2-S2A-C). 
A compendium of perturbational profiles for mitochondrial RNA 
MitoString quantitation of knockdown perturbations provides a valuable 
compendium for gene function prediction and mtDNA transcript characterization. Each 
expression value is normalized to a set of endogenous controls and calculated as a fold-
change compared to shGFP, one of our controls targeting non-human sequences. Since 
PGC-1α induction and LRPPRC knockdown produce the expected mt-mRNA 
perturbations (Figure 2-1C, S2A-C), we have confidence that our dataset can identify 
novel regulators. By hierarchically clustering the average perturbational profile across 
hairpins for each of 107 gene knockdowns along each dimension, we can identify genes 
and mitochondrial transcripts that may have similar functions (Figure 2-2, Table 2-
S3,S4). Unsupervised hierarchical clustering automatically groups LRPPRC and SLIRP 
together with POLRMT, which encodes the RNA polymerase responsible for mtDNA 
transcription, and SSBP1, which encodes a protein required for mtDNA replication 
(Figure 2-2, cluster C1). Separately, genes with roles in mtRNA precursor cleavage, 
including ELAC2 and MRPP1, also form a strong group based on the signature of 
junction probe enrichment (Figure 2-2, cluster C3). Unsupervised hierarchical clustering 
of the MitoString probes results in automated segregation of light strand probes, heavy 
strand mRNAs, and heavy strand junctions (Figure 2-2). Principal component analysis 
further demonstrates the power of our dataset to differentiate these distinct transcript 
types (Figure 2-S1F). In particular, the heavy strand junction and mRNA probes are  
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Figure 2-2. MitoString profiles for 107 gene knockdowns 
Heatmap depicts the log2(fold-change) expression level of each of 27 mtDNA probes 
across 107 gene knockdowns. mtDNA probes are noted along the top, and ordered by 
hierarchical clustering (Euclidean distance). Each gene was targeted by three distinct 
lentiviral hairpins and measured in duplicate. The mean of all hairpins for a given gene 
is displayed and the genes are hierarchically clustered (Euclidean distance). Red 
represents increased and blue represents decreased expression with respect to shGFP. 
Identifiers starting with 'TRN' denote tRNAs. Probe colors are as in Figure 2-1B. 
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 separated by Principal Component 2, which explains 19% of the variance. The lone 
mRNA-mRNA junction, ATP6/8_COX3, is the sole outlier junction, as it behaves like its 
mature products, ATP6/8 and COX3. These unsupervised analyses indicate that many 
genes targeted for RNAi are grouped by function and that mtDNA transcripts respond to 
perturbations in modules. 
Knockdown of LRPPRC or SLIRP depletes all heavy strand mt-RNAs 
 By mining the compendium, we gain insight into the action of LRPPRC and 
SLIRP, which are the strongest regulators tested. Knockdown of LRPPRC or SLIRP 
results in depletion of the heavy strand precursor and all its resulting mt-mRNAs (Figure 
2-2, cluster C1). In addition to LRPPRC and SLIRP, POLRMT and SSBP1 also 
universally deplete heavy strand mt-RNAs when knocked down (Figure 2-2, C1), 
consistent with our expectation that depletion of both precursor and mature transcripts 
should reflect reduced transcription or mtDNA content. SLIRP and LRPPRC form a 
complex known to bind mitochondrial RNA and affect mt-mRNA levels (Mili and Piñol-
Roma, 2003; Sasarman et al., 2010), but reports both supporting and contesting a role 
for LRPPRC in transcription exist (Harmel et al., 2013; Sondheimer et al., 2010). 
Although all heavy strand probes are impacted by shLRPPRC and shSLIRP, some 
junction probes are less strongly affected than the mRNA probes, suggesting a dual role 
for these regulatory proteins in post-transcriptional stabilization and transcription (Figure 
2-1C). One theory consistent with our results is that the complex stabilizes the nascent 
transcript, as suggested elsewhere (Harmel et al., 2013). Because we could quantitate 
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 junction probes strand-specifically, we were able to observe that ND6 and most light 
strand transcripts are unaffected by LRPPRC or SLIRP knockdown. 
MitoString highlights distinct regulatory mechanisms for coding and noncoding 
antisense transcripts  
Querying the MitoString compendium for specific transcripts, such as the heavy 
strand mRNA COX1, uncovers distinct regulation for heavy strand coding and light 
strand noncoding RNAs. We identify nuclear genes whose knockdown alters COX1 
expression relative to the control hairpins, using a rank-sum statistic at a nominal p-
value <0.01 (Figure 2-3A). On the left tail of the distribution, we recover the 
aforementioned LRPPRC and SLIRP. COX1 is also depleted by knockdown of 
FASTKD4 (also known as TBRG4), an uncharacterized protein containing a RAP 
domain with predicted RNA-binding abilities (Lee and Hong, 2004). Hairpins targeting 
the uncharacterized nucleoid component DHX30 also deplete COX1. Interestingly, 
depletion of SUPV3L1, which is implicated in mtRNA degradation, also decreases 
COX1 levels, possibly due to decreased mtDNA copy number, as described previously 
(Khidr et al., 2008). Silencing of MTPAP (mitochondrial poly-A polymerase) also 
diminishes COX1 levels markedly, with the exception of one hairpin (Figure 2-3A). No 
knockdowns significantly increased COX1 expression, perhaps due to its extremely high 
baseline abundance.  
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 Figure 2-3. Discordant expression of junction and noncoding probes highlights 
genes required for processing and degradation  
(A) Expression of the COX1 probe as a log2(expression/shGFP expression) value is 
plotted for each control (green) and knockdown hairpin (blue denotes nominal p-value 
<0.01 by Mann-Whitney rank-sum test when comparing six gene-targeted hairpins to 
the control hairpins shown, grey p-value >0.01). The knockdown of LRPPRC, SLIRP 
and FASTKD4 caused the strongest depletion of COX1. (B) Expression of the rc_COX1 
probe, which targets a noncoding region on the light strand is plotted as in (A). (C) The 
probe count for each knockdown hairpin was plotted for the ND4 mRNA and 
ND4_TRNH junction probes. Genes that disproportionally affect one probe are found 
offset from the diagonal and labeled (Supplemental experimental procedures). Hairpins 
are colored based on knockdown strength (light blue for worst hairpin, blue for middle 
hairpin, dark blue for best hairpin, grey for no knockdown information, and green for 
control). (D) The probe count for each knockdown shRNA hairpin plotted for the ND2 
mRNA and TRNM_ND2 junction probe as in (C)(see also Figure 2-S3). 
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 A similar analysis, focusing on the light strand probe rc_COX1, reveals that the 
majority of significant knockdowns increase rc_COX1 expression (Figure 2-3B). Since 
the noncoding portion of the light strand exists transiently, measuring these regions can 
identify degradation machinery. For the rc_COX1 probe, knockdown of SUPV3L1 
induces a strong increase in transcript levels, confirming the role of SUPV3L1 in this 
process (Figure 2-3B). However, SUPV3L1 silencing actually decreases the level of 
some mt-mRNA transcripts, most notably COX1, COX3, and ND4 (Figure 2-2, cluster 
C3), suggesting that its role in degradation may be selective. The response of COX1 
and rc_COX1 transcripts to systematic RNAi perturbation highlights the distinct 
regulation of heavy strand and light strand transcripts shown in Figure 2-2. 
Identifying negative regulators of mt-mRNA abundance 
We next sought to identify factors that function to repress the abundance of mt-
mRNAs at steady state, in contrast to LRPPRC and SLIRP, which stabilize transcripts, 
by further mining our compendium. Loss of MTG1 (Mitochondrial GTPase 1) expression 
results in an increase of all mt-mRNAs except ND5 (Figure 2-S2D), and it is the second 
strongest scoring gene on the right tail of the COX1 distribution (Figure 2-3A). Although 
it is not significant when summarized by three hairpins for COX1 individually (Figure 2-
3A), measuring multiple genes results in an intriguing phenotype (Figure 2-S2D). MTG1 
has been linked to respiration and translation in human cell lines, but up to now, the 
effect of MTG1 knockdown on mt-mRNA levels had not been measured (Barrientos et 
al., 2003; Kotani et al., 2013). Knockdown of the uncharacterized gene C21orf33 
increases the mt-mRNAs ND1-3, with excellent knockdown-phenotype correlation, but 
31
 has minimal effect on the other transcripts (Figure 2-S2E). In a complementary analysis 
using the GNF Mouse GeneAtlas (Lattin et al., 2008), mRNA expression of the 
C21orf33 mouse homolog is well-correlated with nuclear-encoded OXPHOS gene 
expression (Figure 2-S2F). Our data offers tantalizing clues, but more research is 
required to elucidate the exact roles of these genes. 
Identifying factors that cleave precursor transcripts 
A key advantage of the MitoString approach is that it simultaneously monitors 
both precursor and mature transcripts across a battery of perturbations, allowing 
identification of specific cleavage and processing factors. Within our dataset, known 
cleavage factors form a distinct cluster marked by increased junction expression 
concomitant with stable mt-mRNA expression (Figure 2-2, cluster C3). These recently 
discovered factors include mitochondrial RNase P proteins 1 and 2 (MRPP1 and 
MRPP2), which encode subunits of the tRNA 5’ end cleavage machinery, and ELAC2, 
which cleaves the tRNA 3’ end (Brzezniak et al., 2011; Holzmann et al., 2008; Lopez 
Sanchez et al., 2011). 
By comparing the abundance of specific mt-mRNAs to their unprocessed 
precursor, over all perturbations, we observe a background distribution from which 
outliers represent candidate cleavage factors (Figure 2-3CD). The activity of 
mitochondrial RNase P is estimated by comparing the ND4 transcript with its 
neighboring ND4_TRNH transcript (Figure 2-3C). If the junction is less efficiently 
cleaved, due to gene silencing, more unprocessed RNA will remain (Figure 2-3C). 
Hairpins targeting MRPP1 and MRPP2 have this effect and are consistently distinct 
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 from the background distribution in this case and in others tested (Figure 2-3C, S3A-C). 
We investigate the 3’ cleavage site similarly, by comparing ND2 counts to TRNM_ND2 
counts (Figure 2-3D). In this case, we identify ELAC2, MRPP1, and MRPP2, suggesting 
that knockdown of RNase P components can disrupt 3’ cleavage, as found previously 
for some junctions (Brzezniak et al., 2011; Lopez Sanchez et al., 2011). 
We also interrogate junctions cleaved by non-canonical mechanisms. We find 
that silencing MRPP1-3 or ELAC2 does not influence the ATP6/8_COX3 junction 
cleavage (Figure 2-2, cluster C3 and S3D-F). Further, outlier hairpins for this distribution 
are driven by mt-mRNA depletion, not ATP6/8_COX3 transcript accumulation, leaving 
the cleavage factor for this junction unidentified (Figure 2-S3D-F). The 5’ junction of 
TRNQ on the light strand abuts noncoding DNA and is unexpectedly more strongly 
affected by knockdown of ELAC2 than knockdown of MRPP1/2 (Figure 2-2, cluster C3). 
Conversely, TRNF_RNR1 is more strongly regulated by silencing of MRPP1/2 and 
SUPV3L1 than silencing of ELAC2, although one ELAC2 hairpin still has a strong effect 
(Figure 2-2, C3). Both cases suggest noncanonical processing. 
Impact of known disease genes on mt-mRNA levels 
Our knockdown inventory includes twelve genes implicated in Mendelian 
mitochondrial disease (Table 2-S5). Disease genes MTO1, PUS1, and TRMU encode 
enzymes with well-established roles in tRNA modification and efficient translation, but to 
our knowledge, their role in regulating human mt-mRNA abundance has never been 
tested (Patton et al., 2005; Wang et al., 2010b; Yan and Guan, 2004; Zeharia et al., 
2009). For the strongest MTO1 knockdown hairpin (13% remaining), our compendium 
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 shows depletion of multiple mt-mRNAs (Figure 2-2), confirming similar findings in yeast 
(Wang et al., 2010b). Similarly, strong PUS1 knockdown decreased ATP6, COX3, and 
CYTB mt-mRNA abundance (Figure 2-2). On the other hand, silencing of TRMU has a 
negligible effect on mt-mRNAs (Figure 2-2). In combination, these data suggest that 
some tRNA modifications may be necessary for proper mt-mRNA stability. Disease 
mechanisms may include both improper tRNA modification and mt-mRNA depletion. 
Our compendium also expands our understanding of a number of other disease 
genes (Table 2-S5). A mutation in FASTKD2 has been implicated in cytochrome c 
oxidase (COX) deficiency (Ghezzi et al., 2008), and we now find a 2-fold decrease of 
COX2-3,CYTB, ATP6/8, and ND3-4/4L-5 mt-mRNA expression under FASTKD2 
silencing by at least one hairpin (Figure 2-2). PNPT1, which is implicated in both RNA 
degradation (Borowski et al., 2013) and 5S rRNA, RNase P RNA and MRP RNA import 
(Wang et al., 2010a), has also been recently associated with hearing loss and 
respiratory chain deficiency (Vedrenne et al., 2012; von Ameln et al., 2012). Our data 
reveals moderate increases in short-lived transcripts CYTB and ND2 as well as 
moderate decreases in long-lived transcripts COX1-3 (Figure 2-2) in PNPT1 silenced 
cells, consistent with previous reports and highlighting the complexity of this protein’s 
role in the cell (Borowski et al., 2013). Knockdown of TIMM8A, a known inner-
mitochondrial membrane translocase component targeted in the current study because 
it contains a zinc finger-like motif, is correlated with moderately decreased mt-mRNA 
levels for almost all transcripts (Figure 2-2), and has been previously implicated in 
deafness-dystonia syndrome (Aguirre et al., 2006; Swerdlow et al., 2004). 
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Figure 2-4. Loss of FASTKD4 leads to loss of a subset of steady-state mtDNA 
gene products 
(A) The geometric mean of heavy strand mRNA probe counts divided by the geometric 
mean of heavy strand junction probe counts is plotted for each hairpin. Control hairpins 
are in green and knockdown hairpins are in blue or grey (blue represents nominal p-
value <0.01 by Mann-Whitney rank-sum test). (B) MitoString results normalized to 
shLacZ for five distinct shFASTKD4 hairpins in HEK-293T cells. Control hairpin shown 
in black, FASTKD4 hairpins shown in red. (C) Relative mtDNA content in shLACZ 
knockdown cells compared to shFASTKD4 knockdown cells as measured by qPCR, * 
indicates p <.05 (two-tailed unpaired t-test). (D) Western blot showing expression of 
FASTKD4-FLAG and FASTKD4 (detected by FASTKD4 antibody, top), tubulin (loading 
control, middle), and GFP-FLAG (overexpression control, bottom) in stable HEK-293T  
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 Figure 2-4 (Continued) 
cell lines. Cells are overexpressing RNAi resistant FASTKD4-FLAG and FASTKD4mut-
FLAG (with RAP domain point mutations), or mitoGFP-FLAG in the presence of shLACZ 
(control) or shFASTKD4 knockdown, as indicated. (E) Relative expression of each mt-
mRNA probe quantified by MitoString, shown for the four cell lines depicted in (D). (F) 
Western blot showing expression of FASTKD4 and tubulin in the FASTKD4ko 
CRISPR/Cas9 cell line. (G) Western blot showing expression of FASTKD4-FLAG and 
FASTKD4 (detected by FASTKD4 antibody, top), tubulin (loading control, middle), and 
GFP-FLAG (overexpression control, bottom) in control and FASTKD4ko cell lines with 
overexpression of FASTKD4-FLAG, FASTKD4mut-FLAG, and mtGFP-FLAG as 
indicated (samples run on same gel with irrelevant lane removed). (H) Western blot 
showing respiratory complex protein expression in control and FASTKD4ko cell lines 
with mtGFP-FLAG or FASTKD4-FLAG overexpression as indicated. Three 
concentrations of each cell lysate was loaded as indicated. In all panels, error bars 
represent s.e.m., n=3. 
 
Identifying genes that influence mature mt-mRNA abundance 
To identify genes that specifically stabilize mature heavy strand mt-mRNAs, we 
developed an ordered list that incorporates all of our heavy strand probe data. We 
examined the ratio of the average heavy strand mature mt-mRNA probes to the average 
heavy strand precursor probes for each knockdown gene (Figure 2-4A). Using this 
measurement, we ordered each gene based on the rank-sum of all hairpins targeting 
that gene (Figure 2-4A). This procedure is complementary to Figure 2-3CD, which 
focuses on two individual junctions. Proteins identified through this method might play a 
role in post-transcriptional processing, stability, and degradation. 
POLRMT, which encodes the mitochondrial mtRNA polymerase, is amongst the 
highest scoring hits, causing the ratio of mature mt-mRNA to precursor RNA to increase 
when silenced (Figure 2-4A). POLRMT is well-studied in vitro, but to our knowledge, our 
study is the first to perturb it in vivo. This result suggests that when mtDNA transcription 
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 is reduced, the cell’s response is to stabilize mature mt-mRNAs, via an uncharacterized 
regulatory mechanism. 
A number of genes, when silenced, decrease the ratio of mt-mRNAs to precursor 
transcripts, suggesting that either the nascent strand is stabilized and/or the mt-mRNAs 
are destabilized. As expected, RNase P- and RNase Z-encoding genes (MRPP1, 
MRPP2, ELAC2) are represented here because they stabilize nascent transcripts. 
Knockdown of an uncharacterized gene, FASTKD4, destabilizes mature transcripts and 
has an effect size similar to that produced by knockdown of known regulators (Figure 2-
4A). FASTKD4 clusters in our study with MTPAP and the ribosomal protein-encoding 
MRPS17 (Figure 2-2, cluster C2). In general, silencing of genes in this cluster affects 
the mt-mRNA probes more strongly than the junction probes and does not affect all mt-
mRNAs uniformly. As FASTKD4 has not been previously linked to mt-mRNA expression, 
we pursued its function in more depth. 
Silencing of FASTKD4 depletes some, but not all, mt-mRNAs 
FASTKD4 belongs to a metazoan-specific cohort of proteins, defined by the 
presence of FAST (Fas-activated serine/threonine kinase-like) and RAP (RNA-binding 
domain abundant in Apicomplexans) domains. The human genome encodes six of 
these proteins (FASTK, FASTKD1-5), all of which localize to the mitochondrion (Simarro 
et al., 2010), although not all were identified in the initial MitoCarta compendium 
(Pagliarini et al., 2008). Mutations in FASTKD2 are associated with cytochrome c 
oxidase deficiency (Ghezzi et al., 2008) and FASTKD3 knockdown inhibits respiration in 
cultured cells (Simarro et al., 2010). FASTK encodes a kinase, whose mitochondrial 
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 localization is disrupted during UV- or anti-Fas antibody-induced apoptosis (Li et al., 
2004). FASTK also plays a role in alternative splicing in the nucleus, which requires the 
RAP domain (Izquierdo and Valcárcel, 2007; Simarro et al., 2007). Unlike FASTK, 
FASTKD4 does not have an identifiable kinase active site. 
To confirm our screening result that shFASTKD4 depletes a subset of mt-mRNAs, 
we began by validating the FASTKD4 knockdown phenotype in an independent cell line 
(HEK-293T). We used five distinct hairpins against FASTKD4 and used MitoString to 
measure expression of the mitochondrial transcripts after eight days of stable 
knockdown (Figure 2-4B). In agreement with our initial screen, only a subset of the mt-
mRNA transcripts were affected (COX1-3, ATP6/8, CYTB, ND3), and we show that 
mtDNA is actually increased, ruling out mtDNA depletion as a mechanism (Figure 2-4C). 
ND1 was also consistently upregulated in both cases, while ND2, ND4/4L and ND5 
remained unchanged. Thus, the impact of FASTKD4 silencing on mt-mRNA abundance 
is robust across five distinct hairpin sequences and two cell lines. To confirm that this is 
an on-target effect of FASTKD4 knockdown, we overexpressed a FLAG-tagged RNAi-
resistant FASTKD4 (FASTKD4-FLAG), as well as FASTKD4 with four characteristic 
RAP domain residues mutated to alanines (FASTKD4mut-FLAG) (Figure 2-4DE). 
FASTKD4-FLAG expression, but not FASTKD4mut-FLAG expression, is accompanied 
by recovery in RNA levels for affected transcripts (Figure 2-4E), proving that the 
FASTKD4 knockdown is responsible for the observed phenotype. 
 We next used a complementary gene knockout strategy to perturb FASTKD4 and 
interrogate its impact on OXPHOS protein production. Although the knockdown 
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 produced a reliable RNA phenotype, residual FASTKD4 RNA is translated. We 
generated a FASTKD4 knockout (FASTKD4ko) in HEK-293T cells using the 
CRISPR/Cas9 system (Hsu et al., 2013), which enabled assays in the complete 
absence of FASTKD4. In our FASTKD4ko cell line, we identified three indels at the 
FASTKD4 locus that generate protein-terminating frame shifts, resulting in the absence 
of full-length protein (Figure 2-4F). In FASTKD4ko, we observe reduced abundance of 
complex IV subunit COX2 protein that is rescued by FASTKD4-FLAG overexpression 
(Figure 2-4GH). Complex I, II, III, and V nuclear subunits were unaffected, consistent 
with our screening results and the dependence of these complexes on mtDNA-encoded 
subunits (Figure 2-4H). Thus, two independent genetic strategies indicate that 
FASTKD4 is required for the proper expression of a specific subset of mitochondrial 
RNAs, and in the case of COX2, the protein product. 
Stability of a subset of mt-RNA transcripts requires FASTKD4  
Assuming all heavy strand transcripts are transcribed concurrently, we 
hypothesized that the differential abundance of mt-mRNAs following silencing of 
FASTKD4 is due to differential degradation rates. To measure RNA stability within the 
mitochondrion, we blocked POLRMT-mediated transcription with media containing a 
high concentration of ethidium bromide (ETBR) (Nagao et al., 2008). We quantitated the 
mt-mRNAs using qPCR following six hours of ETBR treatment, during which time period 
mitochondrial transcription is suspended. The fraction of RNA remaining can be 
determined by comparing the ETBR-treated RNA to the untreated RNA. Of the six 
transcripts downregulated at steady state in FASTKD4 knockdown cells (Figure 2-4B),  
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 Figure 2-5. FASTKD4 is required 
for stability of a subset of mt-
mRNAs 
(A) The fraction of RNA remaining 
after ethidium-bromide (ETBR) 
transcription inhibition for 6-hours 
is plotted for each mt-mRNA as 
measured by qPCR in shLACZ and 
shFASTKD4 cell lines. This fraction 
is also plotted specifically for (B) 
COX1 and (C) ND1 in control or 
knockout cell lines expressing 
FLAG-tagged mtGFP, FASTKD4, 
and FASTKD4mut. Error bars 
represent s.e.m., n=3. * represents 
p<=0.05 (two-tailed unpaired t-test). 
 
we find that COX2, ND3, and COX1 also have a strong decrease in the fraction of RNA 
remaining under ETBR treatment (Figure 2-5A), suggesting an increased degradation 
rate. CYTB also trends downward, but not significantly. The only transcripts that are 
depleted (Figure 2-4B) but not destabilized in our assay are COX3 and ATP6/8 (Figure 
2-5A): regulation of these two transcripts, which are part of the stable ATP6/8_COX3 
precursor, appears to be more complicated. By performing the same assay in our 
FASTKD4ko, we observed destabilized COX1, and unchanged ND1, consistent with 
shFASTKD4 (Figure 2-5BC). Further, to rule out off-target RNAi effects, we rescued the 
COX1 destabilization with FASTKD4-FLAG overexpression, but not with overexpression 
of FASTKD4mut-FLAG (Figure 2-5B). 
FASTKD4 associates with mitochondrial RNAs in the matrix  
We sought to define the sub-organellar localization of FASTKD4 relative to the 
mt-mRNAs. FASTKD4, alongside soluble protein Cyclophilin D, was extractable with  
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Figure 2-6. FASTKD4 is localized to the matrix and physically associates with 
mitochondrial RNAs 
(A) Western blot showing the presence of FASTKD4, OXA1L, COX2, and Cyclophilin D 
in isolated mitochondria, with carbonate extraction, and with proteinase K digestion of 
mitoplasts. (B) Western blot showing presence of LRPPRC, FASTKD4, and TFAM after 
immunoprecipitation of each protein or IgG control in control (wt) and FASTKD4ko (ko) 
cells. (C-E) qPCR was used to measure enrichment of (C) COX1 mRNA and (D) 12S 
rRNA, and (E) 18S rRNA with immunoprecipitation of TFAM, FASTKD4, LRPPRC, and 
IgG from wild-type cells. (F-H) qPCR-measured enrichment of transcripts measured in 
C-E with identical immunoprecipitation conditions, but in FASTKD4ko cells. Error bars 
represent s.e.m., n=3. (I) RNA abundance (% input) after FASTKD4 
immunoprecipitation or TFAM immunoprecipitation in wild type cells measured by 
MitoString. (J) RNA abundance (as % input) after LRPPRC immunoprecipitation or 
TFAM immunoprecipitation in wild type cells. Points represent each duplicate. 
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 alkaline carbonate treatment of isolated mitochondria (Figure 2-6A). Additionally, 
FASTKD4 in mitoplasts was resistant to proteinase K treatment, alongside matrix 
protein Cyclophilin D (Figure 2-6A). All measured proteins are substrates for Proteinase 
K. Collectively, these studies indicate that FASTKD4 is a soluble protein residing within 
the mitochondrial matrix. 
Because FASTKD4 appears to stabilize mt-mRNAs, we investigated its binding 
to mtRNA by immunoprecipitating endogenous FASTKD4 from mitochondrial lysates 
and testing for mitochondrial RNA enrichment using qPCR. As controls, we  
immunoprecipitated TFAM, a known DNA-binding protein which is not expected to bind 
to RNA, and LRPPRC, a known RNA-binding protein, alongside FASTKD4 in both 
wildtype and FASTKD4ko HEK-293T cells (Figure 2-6B). In agreement with published 
results (Chujo et al., 2012; Sasarman et al., 2010), LRPPRC is associated with COX1 
mRNA (Figure 2-6C). In addition, LRPPRC associates with 12S rRNA but not nuclear 
18S rRNA (Figure 2-6DE). In comparison, TFAM is not appreciably enriched for either 
RNA (Figure 2-6C and 2-6D). Similar to LRPPRC, FASTKD4 immunoprecipitation 
enriches both COX1 mRNA and 12S rRNA, as compared to TFAM immunoprecipitation, 
in wild type cells, but does not enrich nuclear 18S rRNA (Figure 2-6CDE). Intriguingly, 
FASTKD4 seems to bind 12S almost as strongly as LRPPRC, while it is a weaker 
binder of COX1. In FASTKD4ko cells, RNA enriched from FASTKD4 
immunoprecipitation is indistinguishable from that enriched for TFAM and IgG 
immunoprecipitation, proving that the RNA enrichment of COX1 and 12S rRNA is 
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 specifically due to FASTKD4 immunoprecipitation and is not an antibody artifact (Figure 
2-6FGH). 
 In addition to qPCR, we assessed our TFAM, FASTKD4, and LRPPRC 
immunoprecipitations with MitoString (Figure 2-6IJ). MitoString is valuable in this context 
as it allows strand-specific multiplexed measurement with minimal sample. We found 
that the majority of heavy strand abundant transcripts were enriched in both LRPPRC 
and FASTKD4 immunoprecipitations in comparison to TFAM immunoprecipitation 
(Figure 2-6IJ). In contrast, light strand probes targeting ND6 and light strand intergenic 
space (rc_ND5, rc_ND5_ND6, and rc_TRNQ_TRNM) had less specific enrichment 
(Figure 2-6I). The heavy strand junction probes spanning the RNR2_TRNL1 junction 
and the ATP6/8_COX3 junction are enriched in both FASTKD4 and LRPPRC 
immunoprecipitations. These results for LRPPRC are well correlated with previous 
findings using qPCR (Chujo et al., 2012). In addition, our approach interrogates new 
junction transcripts, especially on the light strand, which do not appear enriched relative 
to TFAM immunoprecipitation. RNR2_TRNL1, which we measure for the first time, is 
enriched in both LRPPRC and FASTKD4 immunoprecipitations at the same level as 
many of the mRNA genes. Our distinct approach and the inclusion of TFAM as a 
negative control demonstrate that FASTKD4 associates with mitochondrial RNAs and 
further validates LRPPRC as a mitochondrial RNA-binding protein. 
Discussion 
The expression of mtDNA requires nuclear-encoded proteins, yet at present, we 
lack a full molecular description of this system. Previous approaches to mitochondrial 
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 RNA measurement, including northern blots, qPCR, and next-generation sequencing, 
have been valuable, but are limited by lack of strand-specificity or sample throughput. In 
the current study, we establish a facile assay, MitoString, to systematically monitor 
precursor and mature mitochondrial RNA species following silencing of over 100 
candidate nuclear-encoded factors. MitoString enables us to identify and classify 
mitochondrial RNA regulators based on their roles in transcription, cleavage, and 
stability. Through this compendium, we have expanded our understanding of previously 
characterized mitochondrial RNA processing proteins and implicated new players in this 
pathway, including the novel regulator FASTKD4. 
Our approach, which measures both mature and precursor transcripts (Figure 2-
1), implicates the LRPPRC-SLIRP complex in production or stability of the heavy strand 
precursor. Previous reports have implicated LRPPRC in promoting transcription (Liu et 
al., 2011; Sondheimer et al., 2010) or the stability of individual mt-mRNAs (Chujo et al., 
2012; Ruzzenente et al., 2012). We find that silencing of SLIRP or LRPPRC primarily 
affects abundance of the heavy strand precursor, indicating a role for the complex in 
either transcription or stabilization of the precursor (Figure 2-2). This decrease is 
accompanied by a more pronounced downregulation of mature heavy strand mt-mRNAs, 
which may suggest a secondary role in mature transcript stability. In contrast, Gohil et al. 
(2010) measured precursors in LRPPRC-silenced cells by qPCR, which is not strand 
specific, and found no change in precursor abundance. Our new method assesses just 
the heavy strand and finds a 4-fold decrease in the same TRNM_ND2 junction upon 
LRPPRC silencing (Figure 2-2). LRPPRC or SLIRP silencing has no effect on the light 
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 strand mRNA ND6 by our assay (Figure 2-2), consistent with strand-specific Northern 
blot measurements (Ruzzenente et al., 2012) and in contrast with strand-insensitive 
qPCR results (Gohil et al., 2010). Recently, GRSF1 has been implicated as a binder and 
regulator of ND6 and its precursor strand, suggesting a distinct mechanism operates on 
the light strand (Antonicka et al., 2013; Jourdain et al., 2013). Additionally, we and 
others find that LRPPRC binds heavy strand transcripts at a higher abundance and 
specificity than light strand transcripts (Chujo et al., 2012), which is consistent with our 
steady-state mtRNA findings. 
We confirm the role of proteinaceous RNase P in the cleavage of tRNA 5’ 
junctions and identify noncanonical cleavage sites. The MitoString profiles of RNase P 
subunits MRPP1 and MRPP2 knockdowns are well correlated, while the effect of 
MRPP3 is weaker (Figure 2-2,3CD). Our comprehensive approach builds on earlier 
findings focused on MRPP1 and a subset of junctions, (Holzmann et al., 2008) as well 
as work focused on MRPP1 and MRPP3 (Lopez Sanchez et al., 2011). We also 
identified a few exceptions to this canonical cleavage process. On the light strand, 
ELAC2 plays a role in the 5’ cleavage of TRNQ, which excises it from surrounding 
noncoding DNA (Figure 2-2, cluster C3). Also, TRNF_RNR1, which we expect to be 
regulated by ELAC2, is more strongly regulated by silencing of MRPP1/2 and SUPV3L1 
(Figure 2-2, cluster C3). Consistent with this, this same TRNF_RNR1 junction was 
previously reported to be unaffected by ELAC2 siRNA knockdown (Brzezniak et al., 
2011). Sequencing results had suggested that knockdown of ELAC2 and RNase P 
components did not affect all tRNA junctions (Lopez Sanchez et al., 2011), but for all of 
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 our tested junctions on the heavy strand (excepting ATP6/8_COX3), either one or both 
were involved (Figure 2-2). The discrepancy may stem from the prior study’s exclusion 
of large precursor fragments due to size selection for tRNA-sized transcripts (Lopez 
Sanchez et al., 2011). Our assay found no obvious candidate for processing of the 
ATP6/8_COX3 junction, as all outlier hairpins are driven by a decrease in mt-mRNA 
levels, not an increase in junction content (Figure 2-S3D-F). 
Although SUPV3L1 clearly plays a role in the degradation of light strand 
transcripts, we find it has contrasting effects on different classes of mt-mRNAs (Figure 
2-2). The short-lived ND1 and ND2 transcripts are increased, whereas the long-lived 
COX1-3 transcripts are actually decreased, suggesting that SUPV3L1 may not be 
responsible for all degradation within the mitochondria. These contrasting effects have 
been previously demonstrated (Szczesny et al., 2010), but only for a subset of mt-
mRNAs. Here we obtained data for all transcripts simultaneously. For the TRNF_RNR1 
and TRNV_RNR2 junctions, which we expect to be a readout for transcriptional initiation, 
hairpins targeting SUPV3L1 are the second strongest inducers of expression (Figure 2-
2,C3). This increased transcription may pertain only to early termination transcripts, 
which end after the second rRNA, since the RNR2_TRNL1 junction and other heavy 
strand junctions are not increased (Figure 2-2, cluster C3). Therefore, SUPV3L1 
depletion may increase ribosome production. 
We find that FASTKD4 regulates a specific subset of mt-mRNAs. FASTKD4 
silencing in general depletes those transcripts that are long-lived while sparing the 
precursor strand (Figure 2-4B). The sole exceptions are ND3, a short-lived depleted 
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 transcript, and ND4/4L, a long-lived unaffected transcript. Most of the affected mt-
mRNAs also have an increased degradation rate in both FASTKD4 knockdown or 
knockout cells (Figure 2-5AB). Thus, we hypothesize that FASTKD4 may be serving to 
shield a specific set of mt-mRNAs from degradation by SUPV3L1 or an as-yet 
unidentified degradation machinery. ATP6 and COX3 unexpectedly do not have an 
increased degradation rate by our assay (Figure 2-5A), however the ATP6/8_COX3 
precursor is the sole mtDNA gene-gene junction and is relatively stable compared to 
other precursors, as estimated by probe counts. The factor responsible for 
ATP6/8_COX3 cleavage remains undetermined and we expect a full understanding of 
this mechanism will resolve the discrepancy we observe. 
We cement a role for FASTKD4 in mitochondrial RNA metabolism based upon 
the above findings, past studies and our immunoprecipitation of FASTKD4-associated 
mt-RNA. FASTKD4 contains a RAP domain in common with experimentally-validated 
RNA-binding proteins (Lee and Hong, 2004) and is found in a genome-wide mRNA-
binding resource (Castello et al., 2012). Here, we show that FASTKD4 is localized to the 
mitochondrial matrix (Figure 2-6A) and associates with mitochondrial RNAs in a specific 
way (Figure 2-6C-I). Our immunoprecipitation assay does not distinguish among the 
heavy-strand transcripts in terms of strength of association with FASTKD4, because this 
protein associates with all heavy-strand transcripts. However, mtRNA susceptibility to 
degradation may be influenced in part by the activity of another, as yet unidentified 
protein that requires FASTKD4 binding. 
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 Why the mitochondrion maintains mt-mRNAs at such disparate levels is unknown, 
but we propose that it may provide a mechanism for ensuring proper OXPHOS complex 
stoichiometry. Across tissues, the molar ratios of different complexes is robust, but the 
mechanism that generates this stability is unknown (Benard et al., 2006). Complex I is 
consistently the least abundant among the OXPHOS complexes (Lenaz and Genova, 
2010), and with the exception of the bicistronic ND4/4L transcript, mtDNA-encoded 
Complex I transcripts have half-lives of less than 90 minutes (Nagao et al., 2008). In 
contrast, Complex IV and V are present at 3-12 times the concentration of Complex I, a 
stoichiometry that we suggest could be metered in part by higher levels of Complex IV 
and V component transcripts (COX1-3, ATP6/8), whose half-lives range 138-231 
minutes. Thus, the precise regulation of mt-mRNA transcript levels by factors like 
FASTKD4 and SUPV3L1 may be important for ensuring proper OXPHOS complex 
stoichiometry and function. 
In the future we anticipate that MitoString may prove useful for interrogating the 
role of mt-mRNA processing directly in tissues from patients with mitochondrial disease. 
Our current study includes the analysis of 12 previously established disease genes 
(Table 2-S5). Of these genes, three had previously been linked to aberrant expression 
of mt-mRNAs in humans. Our current compendium demonstrates that MTO1, PUS1, 
and FASTKD2 loss of function may also cause aberrant expression of mitochondrial 
RNAs. Our results point to additional modes of pathogenesis that may be at play in 
these disorders. As new genetic variants in mitochondrial RNA processing factors are 
identified in patients, a key challenge will lie in proving their pathogenicity. MitoString is 
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 a highly quantitative and systematic approach for measuring mitochondrial gene 
expression that in principle can be easily applied to patient biopsy specimens. 
MitoString may therefore be a useful companion diagnostic for detecting aberrant 
expression of the mtDNA genome in human diseases. 
Experimental Procedures 
Cell culture 
WI-38 fibroblasts and HEK-293T cells were cultured in high glucose DMEM (Invitrogen 
Cat. No. 11995) supplemented with 10% fetal bovine serum (Sigma Cat. No. F6178) 
and 1X penicillin, streptomycin, and glutamine (Invitrogen Cat. No. 10378-016) at 37° C 
with 5% CO2. 
Immunoblotting 
Protein was electrophoresed on a 12% Novex Tris-Glycine polyacrylamide gel at 
constant voltage (125V). The gel was transferred to a polyvinylidene difluoride 
membrane (Trans-Blot Turbo Transfer System). Membranes were blocked for one hour 
at room temperature in tris-buffered saline with 0.1% Tween-20 and 5% BSA (TBST-
BSA). Membranes were incubated with primary antibody in TBST-BSA overnight at 4°C 
(Table 2-S6). Secondary antibody was used at (1:5,000) for one hour at room 
temperature. Membranes were developed using WesternLightning Plus-ECL. 
Screen 
The three best hairpins per gene were selected, and produced and arrayed by the RNAi 
consortium (TRC) as previously described (Moffat et al., 2006). 
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 WI-38 cells were seeded, infected after 24-hours, and selected 24-hours later. 6 days 
post-infection the cells were lysed with RLT buffer (Invitrogen) and β-Mercaptoethanol 
(1:100) and frozen. RLT lysates were processed with a custom MitoString codeset from 
NanoString technologies per manufacturer’s instructions (Geiss et al., 2008). Screen 
details and data processing were as described in supplemental experimental 
procedures. 
Protein expression 
plexFLAG was generated from plex-TRC-983 (TRC) by molecular cloning. pDONR223-
FASTKD4 from a previously described cDNA library (Pagliarini et al., 2008) was 
mutagenized via QuikChange mutagenesis (Agilent) using the primers described (Table 
2-S7). mtGFP was a gift from Y. Sancak.  All cDNAs were cloned into plexFLAG via the 
Gateway system (Invitrogen). 
Lentiviral production and infection 
For follow-up experiments, shRNA lentiviral vectors (TRC) and FLAG-tagged expression 
constructs were used to produce virus and infect HEK-293T cells as previously 
described (Baughman et al., 2009). 4 ug/ml puromycin or 5 ug/ml blasticidin was used 
for selection. 
mtDNA quantitation 
mtDNA quantification was as previously described (Baughman et al., 2009) 
Mitochondrial Isolation / Na2CO3 extraction / Proteinase K protection 
HEK-293T cells were suspended in isolation buffer (220 mM mannitol, 70 mM sucrose, 
5mM HEPES, 1 mM EGTA, pH 7.4 + cOmplete, EDTA-free Protease Inhibitor Cocktail 
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 (Roche)) and lysed using a Cell Disruption Vessel (Parr Instrument Company) 
pressurized to 800 psi with Nitrogen followed by homogenization with five strokes of a 
Teflon Potter Elvehjem homogenizer. Crude mitochondria were isolated by differential 
centrifugation at 600g and 8000g. Mitoplasts were created by swelling with H2O on ice 
and were stabilized in 137 mM KCl, 2.5mM MgCl2, 10 mM HEPES pH 7.2, pelleted at 
8000g and resuspended in isolation buffer. Na2CO3 extraction was performed on crude 
mitochondria and proteinase K protection was performed on mitoplasts as previously 
described (Ryan et al., 2001). 
Measurement of RNA half-lives 
HEK-293T cell lines were seeded the day before exposure to media with and without 1 
ug/ml ethidium bromide. After six hours, the cells were lysed with RLT (Qiagen) for RNA 
extraction. 
RNA isolation and qPCR 
RNA was isolated using the RNeasy protocol with DNase I treatment (Qiagen). cDNA 
was transcribed using Superscript III First-Strand Synthesis Supermix (Invitrogen). 
qPCR was performed with a 7500-FAST ABI instrument and 2X Taqman FAST 
Advanced master-mix (Applied Biosystems) with mt-mRNA probes as described 
previously (Gohil et al., 2010). 
RNA Immunoprecipitation  
Isolated crude mitochondria were lysed in lysis buffer (50 mM HEPES (pH 7.4), 150 mM 
NaCl, 2 mM EDTA, 1% Triton, RNase Inhibitor). Lysates were treated with Turbo DNase 
for 1 hour at 37C. After spinning at 16000g 10 min at 4C, the supernatant was 
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 precleared with Protein A agarose beads for 40 min at 4C with rotation. The beads were 
spun out and the supernatant incubated with antibody overnight at 4C with rotation. 
Fresh Protein A agarose beads were blocked overnight with 1% BSA, 100 ug/ml 
Heparin, 100 ug/ml yeast tRNA in Lysis buffer. The next day, the beads were washed 
3X with lysis buffer, and added to the lysate-antibody mix, and incubated with rotation 
for 2 hours at 4C. The bead complex was washed 3X with lysis buffer, and 3X with 500 
mM NaCl lysis buffer. RNA samples were eluted with 300 ul 1M NaHCO3, 1% SDS at 
room temperature for 15 minutes. Beads were spun down and the supernatant was 
added to 12 ul 5M NaCl. 700 ul of RLT buffer was added for RNA isolation. Protein 
samples were boiled in sample buffer for Immunoblotting. 
CRISPR knockout cell line generation 
sgRNA and U6 primers (Table 2-S7) were used to amplify the pX064 plasmid (gift from 
F. Zhang), as previously described (Hsu et al., 2013). This PCR product was 
cotransfected with the Cas9 plasmid (gift from F. Zhang) into HEK-293T cells with 
XTreme Gene transfection reagent per manufacturer’s instructions. Cells were single-
cell cloned and screened by Western blot for FASTKD4 protein. The identified knockout 
was verified by PCR followed by subcloning and Sanger sequencing. 
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Chapter 3 
Evaluating the pathogenicity of mitochondrial 
gene variants using MitoString 
 
Contributors: Ashley R. Wolf, Daniel S. Lieber, Nancy G. Slate, Steven Hershman, 
Sarah E. Calvo, Katherine B. Sims, Vamsi K. Mootha 
 
Summary 
Despite the widespread use of next-generation sequencing to identify novel 
variants in clinical cases, providing molecular diagnoses to patients with mitochondrial 
disease is challenging. This challenge derives from two issues: (1) the diagnosis of 
mitochondrial disease is challenging due to phenotypic and genetic heterogeneity and 
(2) assigning pathogenicity to variants requires both enrichment in patients and 
laboratory complementation experiments. In the case presented here, we have a patient 
with a suspected mitochondrial disorder and no family history, who was found to have 
variants of unknown functional significance in SUPV3L1, the gene encoding a helicase 
involved in mitochondrial RNA degradation. No mutations in SUPV3L1 had been 
previously linked to disease. In the laboratory, we used MitoString, a technique for 
interrogating mitochondrial RNA transcripts in parallel, to probe patient fibroblasts. We 
found that the patient fibroblasts did not look appreciably different from control 
fibroblasts, while genetic disruption of SUPV3L1 resulted in accumulation of 
mitochondrial DNA light strand RNA transcripts. Thus, we found no evidence for 
pathogenicity of the SUPV3L1 variants in our fibroblast model. Subsequently, other 
 researchers identified pathogenic variants in a non-mitochondrial gene, N-glycanase 1 
(NGLY1), which accounted for the patient’s features. Our study underlines the challenge 
of variant interpretation and the power of laboratory techniques, including MitoString, to 
assess variant pathogenicity in difficult cases. 
Background 
Mitochondrial disease can present in infancy or adulthood and is characterized 
by a wide range of presentations affecting multiple organ systems. Common symptoms 
include lactic acidosis, myopathy, deafness, blindness, neurodegeneration, intestinal 
dysmotility and peripheral neuropathy (Vafai and Mootha, 2012). Although mitochondrial 
disease is one of the most abundant inborn errors of metabolism (1:5000 live births), 
there are no effective treatments and diagnosis is far from straightforward (Sanderson et 
al., 2006). Clinical, biochemical, and molecular criteria are applied to determine the 
likelihood of a patient having mitochondrial disease based on their presentation of 
symptoms and lab results (Morava et al., 2006). However, recent work has found that a 
number of non-mitochondrial diseases can present with a clinical picture 
indistinguishable from mitochondrial disease (Lieber et al., 2013). 
Next-generation sequencing has proven invaluable for genetic diagnosis, but 
patients suspected of mitochondrial disease provide a striking example of the limitations 
of this approach. A recent cohort of 102 patients suspected of mitochondrial disorders 
established molecular diagnosis in just 22% of cases by MitoExome sequencing, which 
targets genes encoding mitochondrial-localized proteins (Lieber et al., 2013). In an 
additional 26% of cases, Lieber et al. is able to prioritize variants of unknown 
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 significance that may cause disease. However, absent additional experimental proof, 
these variants cannot be deemed pathogenic. To prove the pathogenicity of genetic 
variants in cases without a history of Mendelian transmission, Chakravarti et al. have 
proposed a version of Koch’s postulates for Complex Human Disease. The first criteria, 
that candidate gene variants are enriched in patients, is provable by exome-sequencing 
alone, but the remainder of the criteria require a model system with a disease-relevant 
human phenotype. Further, they require proof at two levels: first, the mutant allele must 
be proven responsible for a mutant phenotype in a model system, and second, the 
model phenotype must be accepted as equivalent to the human disease. For the first 
level, this model phenotype must be produced by disruption of the candidate disease 
gene, complemented by a wild-type human allele, and not complemented by the 
candidate variant (Chakravarti et al., 2013). Thus, molecular experiments are necessary 
in addition to sequencing to close the circle on diagnostic dilemmas. 
In the following case, the clinical presentation was suggestive of mitochondrial 
disease and the patient underwent targeted MitoExome sequencing (Calvo et al., 2012; 
Lieber et al., 2013), which identified compound heterozygous variants in the gene 
SUPV3L1, which encodes a mitochondrial-localized protein. SUPV3L1 is a helicase 
implicated in mitochondrial RNA degradation, and previous research established that a 
dominant negative form of SUPV3L1 increased build up of light strand noncoding 
transcripts in a cellular model (Szczesny et al., 2010). We investigated whether the 
patient-derived cell line had a similar phenotype to the validated dominant negative, in 
order to determine if we could use this model to test the candidate disease variants.  
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 Case Presentation 
A two-year-old female of European descent was referred to the mitochondrial 
disease clinic with hypotonia, failure to thrive, light twitching, and developmental delay 
(language). She had a history of constipation and an enlarged spleen upon exam. Upon 
further testing, she exhibited problems with her eyes (bilateral strabismus) and ears 
(right-sided mild hearing loss, left-sided sensorineural loss in the upper frequencies). 
The patient had persistent mild elevation of liver function tests and intermittent 
mildly elevated lactate levels. In liver biopsies, the mitochondrial DNA (mtDNA) copy 
number was 39% of controls and electron microscopy identified abnormal, enlarged 
mitochondria with a depletion of cristae. These multi-systemic findings suggested the 
possibility of a mitochondrial disorder. 
Results 
The patient was enrolled in the mitochondrial disease registry at Massachusetts 
General Hospital. We performed MitoExome sequencing (Calvo et al., 2012) on the 
patient and her parents under the hypothesis that her disease was the result of a 
mutation in a gene encoding a mitochondrial-localized protein. During MitoExome 
sequencing, the mtDNA and 1600 nuclear genes encoding mitochondrial proteins and 
related disease genes were enriched by hybrid capture and sequenced. 
In the patient’s sequenced nuclear DNA, we identified 36 rare (<2% allele 
frequency in 1000Genomes), protein-modifying variants. Hypothesizing a recessive 
model of inheritance, we screened these 36 variants for either homozygous or putatively 
compound heterozygous variants. We identified no homozygous variants and two 
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 variants in the gene SUPV3L1, which were confirmed to be compound heterozygous 
after phasing with the parental DNA. Both mutations, c.505A>G / p.I169V (<1:8000 
allele frequency) and c.2075C>T / p.P692L (1.6% allele frequency), altered residues 
that were moderately to highly conserved and predicted to be “benign” by Polyphen2 
(Table 3-1). SUPV3L1 encodes a helicase implicated in degradation of mitochondrial 
RNA. Each mutation altered an amino acid residue in a protein required for appropriate 
mitochondrial function, so we proceeded to assess the effect of these mutations in a 
patient-derived fibroblast cell line and two healthy control cell lines. 
First, we measured baseline SUPV3L1 protein expression in the patient and 
control cell lines. We observed equivalent SUPV3L1 expression in each cell line tested 
(Figure 3-1A). Thus, at least one patient variant generates a full-length, stable SUPV3L1 
protein in fibroblasts. This does not confirm that the observed SUPV3L1 is functional, 
and therefore we proceeded to measure mitochondrial RNA levels. 
Previous studies had established a signature of SUPV3L1 dysfunction, which we 
leveraged to assess the function of our variants within the fibroblast cellular model. 
Szczesny et al. identified a SUPV3L1 dominant negative (SUPV3L1dn) that stabilizes 
light strand noncoding transcripts. Using MitoString, which profiles mitochondrial  
Table 3-1. Prioritized variants 
Gene 
symbol Protein Chr:Pos cDNA
* Ref.
codon
Var.
codon
Allele
Freq **
SUPV3L1 p.I169V 10:70947445 c.505A>G ATA GTA <1:8,000
SUPV3L1 p.P692L 10:70968505 c.2075C>T CCA CTA 1.6%***
*     Transcript  NM_003171, “+” strand
**   Exome Variant Server (EVS), European Americans (EA)
***  Three p.P692L EA homozygotes in EVS (N=4300)
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 RNA expression, we found that SUPV3L1 knockdown elevates light strand noncoding 
transcripts, while depleting some mitochondrial mRNAs (Chapter 2). Here, we use 
MitoString to assess whether the patient cell line has any features of SUPV3L1 
dysfunction, which would establish a cellular model for more thoroughly testing the 
pathogenesis of the candidate variants. 
 In patient and control cell lines, we stably overexpressed wildtype SUPV3L1 and 
SUPV3L1dn, as well as GFP and SLIRP as controls and assessed mitochondrial RNA 
expression (Figure 3-1B). Our MitoString assay measured two noncoding light strand 
transcripts in the regions complementary to COX1 (antiCOX1) and ND5 (antiND5). 
Each of these transcripts was elevated during SUPV3L1dn expression, in each cell line 
tested (Figure 3-2). However, there is no difference between control and patient 
fibroblasts at baseline, suggesting SUPV3L1 function is not compromised in the patient 
fibroblasts. Further, overexpression of wild type SUPV3L1 is indistinguishable from 
overexpression of the controls mtGFP and SLIRP. 
Figure 3-1. Protein expression in fibroblast control and patient cell lines. 
(A) Baseline expression of SUPV3L1, ACTB, and mtCOX2 protein in control and 
patient-derived fibroblast cell lines by Western blot. (B) Overexpression of mitoGFP-
FLAG, SUPV3L1-FLAG, and SUPV3L1dn-FLAG in control and patient cell lines. 
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Figure 3-2. mtRNA expression in control and patient cell lines. 
Expression of anti_ND5 (A), anti_COX1 (B), COX2 (C), and ND6 (D) transcripts in 
control and patient cell lines overexpressing FLAG-tagged mtGFP, SLIRP, SUPV3L1dn, 
and SUPV3L1. 
 
The heavy strand transcript COX2 was reliably depleted by SUPV3L1dn 
expression, but again, the patient cell line was not rescued in any way by wild type 
SUPV3L1, and in fact overexpression of SUPV3L1 looked more like the dominant 
negative than GFP. Taken together, these results did not offer any evidence of a 
SUPV3L1-mediated defect in our patient cell line. 
Conclusion 
Despite leveraging advanced genetic and experimental techniques for the 
genetic analysis and variant interpretation, we were unable to assign a molecular 
diagnosis in this case. However, MitoString proved valuable in assessing a set of 
putative pathogenic variants in the gene SUPV3L1, as previous studies had established 
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 the expected cellular phenotype for SUPV3L1 disruption. We find that introduction of a 
SUPV3L1dn protein disrupts degradation of light strand transcripts, while patient 
fibroblasts were indistinguishable from controls in this respect. Further, introduction of 
wildtype SUPV3L1 did not have a differential effect on patient versus control cells, 
further confirming the lack of a measurable defect in our cellular model. 
When a gene is well understood in a cellular context, putative pathogenic 
variants can be easily tested through cellular assays and re-introduction of the wild type 
and variant construct. In addition to enrichment of variants in affected individuals, this 
experimental proof is necessary to firmly establish pathogenicity within the model 
system (Chakravarti et al., 2013). A second level of proof, equivocating the model and 
the human disease is also necessary, and we do not explore that here. In the case 
explored here, we found no evidence that SUPV3L1 function was compromised in our 
fibroblast model. In fact, subsequent whole-exome sequencing revealed mutations in N-
glycanase 1 (NGLY1) that are considered causal (Enns et al., 2014). NGLY1 is a 
cytoplasmic enzyme that degrades misfolded glycoporoteins as a component of the 
endoplasmic reticulum–associated degradation machinery. This finding highlights that 
mutations in genes encoding non-mitochondrial proteins can mimic as mitochondrial 
disorders in a clinical context. 
Experimental procedures 
MitoExome sequencing and variant detection 
MitoExome sequencing was as described previously (Lieber et al., 2013). 
Specifically, we targeted 3.1 Mb of DNA including the mtDNA and coding exons of 1,598 
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 nuclear- encoded genes: 113 genes known to cause mitochondrial disease, 945 high-
confidence mitochondrial genes from MitoCarta (Pagliarini et al., 2008), 327 genes 
predicted to associate with mitochondrial function, and 213 genes underlying monogenic 
disorders in the differential diagnosis, i.e., metabolic and neurologic disorders with 
phenotypic similarity to mitochondrial disease.  
DNA was extracted from Epstein-Barr virus–immortalized lymphoblastoid cell 
lines. Targeted DNA regions were captured and sequenced (paired-end 76 base pair 
reads, Illumina GA-IIx or Hi-Seq) at the MGH Next-Generation Sequencing Core. 
Sequence alignment, variant detection, and annotation were performed as previously 
described (Lieber et al., 2013).  
Variant prioritization 
We identified variants with allele frequency <2% in 1000 Genomes Project (low 
coverage release 20110511) (Abecasis et al., 2010) and prioritized the following nuclear 
variants: i) known pathogenic variants (Human Gene Mutation Database version 
2010.3) (Stenson et al., 2009), and ii) variants that were likely deleterious, including 
nonsense, splice site, coding indel, and missense variants at sites conserved in ≥ 10 of 
44 aligned vertebrate species (Calvo et al., 2012). All prioritized variants were manually 
reviewed to remove likely sequencing artifacts and to phase potential compound 
heterozygous variants (Lieber et al., 2013). 
Cell Culture 
Patient and control fibroblasts were obtained from Gregory Enns and grown in 
Memα media (Life technologies 12571-063) with 17% fetal bovine serum (Sigma Cat. 
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 No. F6178) with 1X penicillin, streptomycin, and glutamine (Life Technologies Cat. No. 
10378-016) at 37° C with 5% CO2. 
FLAG-tagged protein expression 
plexFLAG and mitoGFP were generated as described in Chapter 2. pDONR223-
SUPV3L1 and pDONR223-SLIRP were obtained from a previously described cDNA 
library (Pagliarini et al., 2008). The SUPV3L1dn G207V (GGC->GTC) mutation was 
introduced via QuikChange mutagenesis (Agilent) using Primer 1: 5’-
GATAATATTTCATTCAGTCCCCACAAACAGTGG and Primer 2: 5’- 
CCACTGTTTGTGGGGACTGAATGAAATATTATC. All cDNAs were cloned into 
plexFLAG via LR reaction (Invitrogen). The plexFLAG constructs were used to produce 
virus and infect HEK-293T cells as previously described (Baughman et al., 2009). 
Selection was introduced for two weeks with 5 ug/ml blasticidin. 
MitoString Assay 
Fibroblasts were lysed with RLT buffer (Invitrogen) and frozen at -80C. RLT 
lysates were hybridized overnight at 65C with a custom MitoString codeset (described in 
Chapter 2) from NanoString technologies, and processed with the nCounter robotic 
system per manufacturer’s instructions (Geiss et al., 2008). 
Immunoblotting 
Fibroblasts were lysed with RIPA buffer and protein was loaded on a 12% Novex 
Tris-Glycine polyacrylamide gel (Life Technologies) and electrophoresed at constant 
voltage (125V). The gel was transferred to a polyvinylidene difluoride membrane using 
the Trans-Blot Turbo Transfer System (Bio-Rad). Membranes were blocked for one 
hour at room temperature in tris-buffered saline with 0.1% Tween-20 and 5% BSA 
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 (TBST-BSA). Membranes were incubated with primary antibody: anti-GFP (Abcam 
AB291) 1:50000, anti-SUPV3L1 (gift of W.Lee, UC-Irvine) 1:2000, anti-TUB (cell 
signaling #2128) 1:2000 in TBST-BSA overnight at 4°C. Mouse (1:5000) and Rabbit 
(1:10000) secondary antibody was used for one hour at room temperature. Membranes 
were developed using WesternLightning Plus-ECL (PerkinElmer). 
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Chapter 4 
Characterization of the mitochondrial 
transcriptome in mouse liver 
 
Contributors: Ashley R. Wolf, Xian Adiconis, Joshua Z. Levin, Vamsi K. Mootha 
 
Summary 
Approximately 1,100 nuclear proteins are imported into the mitochondria, through 
well-characterized import machinery, but the presence and role of mitochondrial-
imported RNA is debated. Import of nuclear-encoded 5S rRNA and the enzyme 
components MRP RNA and RNase P RNA have been described. Although the 22 
tRNAs encoded by mtDNA have been considered sufficient for mitochondrial translation, 
import of nuclear tRNAs is also reported. Here we use sequentially purified 
mitochondria, an approach that has been successfully used to characterize the 
mitochondrial proteome, to characterize the mitochondrial transcriptome in mouse liver. 
We find strong enrichment of mitochondrial proteins and mtDNA-encoded transcripts in 
our mitochondrial samples. Nuclear-encoded 5S rRNA is persistent in our mitochondrial 
samples, consistent with previous reports, but we do not observe mitochondrial import 
of nuclear tRNAs, in contrast with several recent mammalian studies. We discuss the 
possible reasons for this discrepancy and the challenges of using genome-wide 
sequencing to identify nuclear-imported transcripts. 
 
 
	  	  
Introduction 
Mammalian mitochondria contain their own genome (mtDNA), which encodes 2 
rRNAs, 22 tRNAs and 11 mRNAs. These transcripts are extremely abundant within 
mitochondria, and are essential for proper function of the respiratory chain. Roughly 
1,100 nuclear encoded proteins are translocated into the mitochondria by well-
established protein translocation machinery. However, there is much debate about 
which RNAs may be imported into the mitochondria, and how exactly they are imported. 
Various reports have identified nuclear-encoded miRNAs, sRNAs, tRNAs, and rRNA 
within mammalian mitochondria (Kren et al., 2009; Mercer et al., 2011; Rubio et al., 
2008; Yoshionari et al., 1994). 
Two mitochondrial-localized enzymes contain nuclear-encoded RNA 
components. The first, RNase MRP, is the endonuclease responsible for cleavage of 
the RNA primer required for mtDNA replication (Chang and Clayton, 1987). The RNase 
MRP RNA is dually partitioned to the nucleoli and cytoplasm, however it interacts with a 
distinct protein to perform its enzymatic activity in each location (Li et al., 1994; Lu et al., 
2010). Mitochondrial RNAse P activity cleaves the 5’ end of mitochondrial tRNAs. Both 
a protein-only complex and a protein-RNA complex have been assigned this activity 
(Holzmann et al., 2008; Puranam and Attardi, 2001). The RNA component of 
mitochondrial RNase P, like RNase MRP, is identical to the nuclear version, thus must 
be imported into mitochondria (Puranam and Attardi, 2001). The mitochondrial protein 
polynucleotide phosphorylase (PNPase) stimulates import of both the MRP and RNase 
P RNAs, but the exact mechanism remains unclear (Wang et al., 2010). 
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Import of nuclear-encoded 5S rRNA into mammalian mitochondria has been 
biochemically characterized, confirming that RNA import into the mammalian 
mitochondria is possible (Magalhaes et al., 1998; Yoshionari et al., 1994). In fact, 
specific aspects of the RNA sequence have been identified as essential for import 
(Smirnov et al., 2008) and an import system involving the proteins rhodanese and 
MRPL18 has been described (Smirnov et al., 2010; Smirnov et al., 2011). Depletion of 
rhodanese, which decreases mitochondrial-localized 5S rRNA, also decreases 
mitochondrial translation (Smirnov et al., 2010; Smirnov et al., 2011). PNPase also 
augments 5S rRNA import (Wang et al., 2010). 
The 22 tRNAs present in the mammalian mitochondria are sufficient to decode 
the mtDNA-encoded mRNAs, if wobbling of the third anticodon base is allowed, 
enabling the tRNAs to match more than one codon (Chomyn and Attardi, 2009). 
However, this idea has been challenged by the discovery of a nuclear-encoded 
glutamine tRNA in mammalian mitochondria (Rubio et al., 2008). Mitochondrial tRNA 
import has been described for Tetrahymena, trypanosomatids, yeast, plants, and 
marsupials (reviewed in Tarassov et al., 2007), but this was the first mammalian 
example, and the import pathway is unknown (Alfonzo and Soll, 2009). 
A recent study that performed RNA sequencing on mitochondria and 
mitochondria matrix fractions from human cells identified multiple tRNAs localized to the 
mitochondria (Mercer et al., 2011). The identified tRNAs are encoded at multiple 
locations in the nuclear genome, including regions containing nuclear copies of 
mitochondrial DNA (NUMTs). NUMTs are regions in the nuclear genome that are near-
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copies of the mitochondrial genome, inserted into the nuclear genome over evolution. 
Humans have 286 to 612 NUMTs present in the genome, with the largest spanning 90% 
of the mtDNA genome (Hazkani-Covo et al., 2010). NUMTs often contain regions that 
are just a few bases different from the mitochondrial genome, which makes it difficult to 
distinguish NUMTs from mtDNA using modern sequencing techniques, which can lead 
to identification of mtDNA “mutations”, which are in fact NUMTs differing from mtDNA by 
a single base for a given sequencing read (Wallace et al., 1997). In identifying imported 
tRNAs located within NUMTs, it is possible that this identification occurred using reads 
that were inadvertently mismapped to the nuclear genome, when they were in fact 
transcribed from mtDNA (Mercer et al., 2011). 
 Given the evidence that specific RNAs are imported into the mitochondria, we 
sought to validate previous findings and identify novel imported transcripts using an 
unbiased approach. Our approach complements the findings of Mercer et al., which 
performed RNA sequencing on isolated mitochondria and mitoplasts from human cells. 
We isolated mitochondria from mouse liver by sequential enrichment, which allows us to 
observe enrichment of transcripts across four samples of increasing mitochondrial 
purity. By using two different RNA sequencing approaches, we were able to scan the 
mitochondrial transcriptome for full-size and tRNA-sized imported RNAs. In contrast to 
Mercer et al., we find no evidence for enrichment of novel nuclear-encoded transcripts. 
In particular, despite good coverage of the nuclear tRNAs, we observe no evidence for 
import into mouse mitochondria. 
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Results 
Sequential mitochondrial enrichment enriches mitochondrial proteins 
To identify the transcriptome present within mitochondria, we isolated four 
samples at different levels of mitochondrial purity from mouse liver (Figure 4-1A). First, 
whole tissue lysate was sampled directly after homogenization of the liver. Next, crude 
mitochondria were isolated from the homogenate by differential centrifugation. To 
degrade nucleotides clinging to the outside of the mitochondria, we incubated the crude 
mitochondria in Micrococcal Nuclease (MNase). Finally, we inactivated the MNase and  
 
Figure 4-1. Sequential mitochondrial enrichment 
(A) Mitochondria were isolated from mouse liver by differential centrifugation (crude 
mitochondria) then treated with MNase and further purified over a Percoll density 
gradient. RNA was isolated from each sample and two different RNA sequencing 
libraries were generated, as noted. (B) Western blot for mitochondrial protein 
abundance performed with protein from each sample in (A). 
HSP60
CYTC
VDAC
ACTB
Wh
ole
 tis
sue
 lys
ate
Cru
de 
mit
och
ond
ria
MN
ase
-tre
ate
d m
itoc
hon
dria
Pe
rco
ll-p
urif
ied
 mi
toc
hon
dria
 crude
mitochondria
MNase-treated
mitochondria
percoll-purified
MNase treated
mitochondria 
liver
whole tissue 
lysate 
Library 1
strand-specific
paired-end
76-bp read
sequencing
[RNAs > 160bp]
Library 2
single-end
36-bp read
sequencing
[50 bp < RNAs < 100 bp]
RNA
RNAseq
library1
RNAseq
library2
RNA
RNAseq
library1
RNAseq
library2
RNA
RNAseq
library1
RNAseq
library2
RNA
RNAseq
library1
RNAseq
library2
A B
77
	  	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-2. RNA expression of mitochondrial rRNA transcripts 
For each sample, RNA-seq coverage from the large strand-specific library is visualized 
as generated by igvtools summarizing the Tophat alignment across 5 bp windows. The 
position of rRNAs and tRNAs (demarcated by one-letter code) encoded on the heavy 
strand of the mtDNA genome are depicted in grey at the bottom. 
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purified the treated mitochondria over a Percoll density gradient. Each step of this 
procedure enables more removal of non-mitochondrial contaminants. 
We isolated protein from each sample and measured mitochondrial-localized 
proteins alongside actin (ACTB), an abundant cytoplasmic contaminant (Figure 4-1B). 
We find that the matrix-localized protein HSP60, inner membrane space protein CYTC 
and outer membrane protein VDAC are all enriched, while ACTB is depleted, as the 
samples are sequentially enriched for mitochondrial content. This confirms that we have 
achieved mitochondrial enrichment, and so we proceeded to RNA isolation. 
Transcripts from the mitochondrial genome are enriched in large RNA library 
We isolated RNA from the four samples and developed two distinct RNA-seq 
libraries. First, we created a strand-specific RNA-seq library for detecting large RNAs 
greater than 160 base pairs (bp) and performed paired-end sequencing with 76 bp 
reads. This library was not poly-A selected, in order to capture diverse transcripts types.  
In the large library, we clearly see enriched coverage of the mitochondrial rRNAs and 
mRNAs (Figure 4-2,3). The mitochondrial rRNAs are an order of magnitude more 
abundant than the most abundant mRNAs (Figure 4-2). Reads for the light strand in this 
region are not detected. As expected, the long-lived mRNAs Cox1-3 and Atp6/8 are 
more abundant than the other transcripts (Figure 4-3). Although gene-to-gene 
comparisons may be affected by sequencing efficiency, the difference is striking. As 
predicted by our size selection for transcripts greater than 160 bp, the tRNA transcripts 
are not well represented in this library (Figure 4-3). 
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Figure 4-3. RNA expression across the mtDNA genome 
For each sample, RNA-seq coverage from the large strand-specific library is visualized 
as generated by igvtools summarizing the Tophat alignment across 5 bp windows. The 
position of mRNAs and tRNAs (demarcated by one-letter code) encoded on the heavy 
strand (grey) and light strand (red) of the mtDNA genome are depicted at the bottom. 
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As evidenced in Figure 4-3, the light strand is very lightly transcribed, and Nd6 
transcription is only apparent from the final enrichment step. Interestingly, the Nd6 
transcript continues into the sequence complementary to Nd5, as previously reported for 
human mtDNA (Rackham et al., 2011). We also see marked transcription upstream of 
the first light strand tRNA, between Nd6 and the light strand promoter, which may 
include transcripts serving as the replication primer (Figure 4-3). 
No tRNA import observed 
 To test reports of tRNA import into the mitochondria, we selected RNA transcripts 
from 50-100 bp in length from the whole tissue lysate and each of our mitochondrial 
enriched samples. We developed a protocol involving synthetic poly-A addition in order 
to sequence these short transcripts, which may be tRNAs of both mitochondrial and 
nuclear origin. This tRNA library was sequenced with single-end 36 bp reads.  
Although 5S rRNA at 121 bases is technically above our size threshold, we still 
have reasonable coverage of this RNA in our tRNA library, and it serves as a control for 
our study. The import of 5S rRNA into the mitochondria has been biochemically studied, 
but a recent sequencing study noted only modest persistence of the transcript, as it is 
also abundant in the cytosol (Entelis et al., 2001; Mercer et al., 2011). By directly 
mapping to the 5S rRNA reference sequence, we find that our crude mitochondrial 
sample contains 40% of the 5S rRNA found in the whole tissue lysate sample, 
consistent with previous reports (Mercer et al., 2011) (Figure 4-4A). 
We tested for tRNA import by analyzing our dataset in two distinct ways. We first 
aligned, allowing one mismatch, to a validated list of tRNAs (Chan and Lowe, 2009) and 
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the mtDNA-encoded tRNAs. As discussed, with this approach the crude mitochondrial 
sample contains 40% of the whole tissue lysate, and subsequent enrichments with 
MNase and Percoll did not decrease the 5S rRNA abundance, suggesting residence 
within the mitochondrion (Figure 4-4A). In contrast, nuclear tRNAs ArgTCT and LeuTAA 
are markedly depleted with each step of the enrichment, suggesting they are abundant 
cytoplasmic contaminants (Figure 4-4A). Similarly, all nuclear tRNAs tested are 
depleted markedly in the mitochondrial-enriched samples (Figure 4-4B). The 
mitochondrial tRNA Leu1 is 10-fold enriched, as it exists only within the mitochondrion 
(Figure 4-4A). When testing all tRNA transcripts, we found that the only tRNAs that were 
enriched were those that were mitochondrial-encoded (Figure 4-4B). 
Figure 4-4. Expression of tRNAs and 5S rRNA 
(A) Fold-enrichment of transcripts is shown across each sample, with whole tissue 
lysate normalized to 1. (B) Log2 (fold-enrichment) shown for each mtDNA-encoded 
tRNA (red) and nuclear-encoded tRNA (black) across all four samples, with whole tissue 
lysate (WTL) normalized to 0. 
 
 As previous reports had found mitochondrial enrichment of nuclear tRNAs in rat 
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tRNAs by the RepeatMasker database. Only one annotated tRNA has a non-zero value 
for all four samples and an increased rpkm value for each mitochondrial sample that 
exceeds the whole tissue samples. That is tRNA-Gln-CAA_ on chr12, which contains a 
41-nucleotide span that is identical to mtDNA, since it exists within a NUMT. Thus reads 
from mtDNA can map to this nuclear transcript, likely falsely suggesting it is imported. 
This region was not annotated as a tRNA by the database used in the first analysis.  
No novel imported transcripts observed 
We also probed our large RNA-seq library to identify the RNase MRP and RNase 
P RNAs and any novel transcripts that might be imported. Unfortunately, the RNase 
MRP and RNase P RNAs were not well detected due to their low abundance, which has 
been previously remarked upon (Mercer et al., 2011). We used the Cufflinks software 
package to identify transcripts de novo based on the mouse genome sequence, and 
also used the Trinity software package to identify transcripts de novo without any 
genome assumed (Grabherr et al., 2011; Trapnell et al., 2010). In both cases, we found 
no mitochondrial-enriched transcripts. However, as noted, the 5S rRNA transcript is not 
enriched with sequential mitochondrial purification steps, just persistent, so we also 
relaxed our threshold. We found that transcripts mapping to the extremely abundant 
LSU-rRNA_Hsa repeat, which encodes multiple rRNA transcripts, were also persistent. 
However, there was no specific sequence within this large repeat that was found to be 
systematically enriched, and these repeats also contain many repetitive elements that 
might cause mapping issues. 
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Discussion 
 The RNAs 5S, RNase MRP, and RNase P RNAs have been biochemically 
proven to be imported into the mammalian mitochondria, but they were not striking in 
our RNA-seq dataset. The RNase MRP and RNase P RNAs were of too low abundance 
to be quantitated, and the 5S rRNA was merely persistent, not necessarily enriched. 
Due to the high concentration of 5S rRNA in the cytoplasm, this is perhaps expected, as 
mitochondrial abundance of 5S may be lower than cytosolic abundance of 5S. This 
quantitation is also consistent with what was found in human mitochondria with a similar 
approach (Mercer et al., 2011). However, the difficulty in picking up these known 
imported transcripts highlights the challenge of identifying new imported transcripts by 
unbiased genomic approaches. Noncoding RNAs of low abundance like the RNase 
MRP and RNase P RNAs may exist, but we may have not sequenced deep enough to 
detect them. 
Although Mercer et al. find a number of tRNAs enriched in their mitoplast 
preparation when compared to the mitochondria, we do not find any evidence for 
mitochondrial import of nuclear tRNAs. Both biological and technical reasons may 
contribute to this discrepancy. Biologically speaking, Mercer et al. used mitochondria 
isolated from human cells, while we used mitochondria purified from mouse liver. It is 
possible that humans have developed import of tRNAs in a way distinct from mouse, or 
that this import is cell-type specific. 
  Technically, Mercer et al. used mitoplasts, a mitochondrial matrix preparation 
which removes the outer membrane, and may have acquired different information with 
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this method. We do however see similar 5S rRNA persistence, and enrichment of the 
mtDNA encoded tRNAs with our method (Figure 4-4A), suggesting that we have 
reasonable power to detect transcripts. Mercer et al. find that tRNA-LeuTAA and tRNA-
GlnTTG are enriched. We do measure each of these, although our tRNA-GlnTTG is of 
low abundance, which may have affected our detection. When looking at the human 
tRNA list they used to compile measurements (Chan and Lowe, 2009), we noticed that 
two of the seven sequences used to compile counts for tRNA-LeuTAA fell in human 
NUMTs, as well as one of the eleven sequences encoding tRNA-GlnTTG. None of the 
mouse sequences attributed to tRNA-LeuTAA and tRNA-GlnTTG have significant 
homology to mtDNA. This may mean that either regions that encode human NUMTs are 
more likely to be imported into the mitochondria, or that sequencing and mapping errors 
cause alignment to the nuclear genome when they are actually transcribed from mtDNA. 
 Biochemical characterization like that undertaken to validate the import of 5S 
rRNA is necessary to determine the validity of tRNA import, as genomic reports have 
provided conflicting results. The reason for these discrepancies require further 
investigation. However, our dataset and approaches like it may also be valuable for 
categorizing reads as NUMT vs. mtDNA, as we expect NUMTs to be transcribed and 
depleted as mitochondrial purity increases, while mtDNA originating transcripts will be 
enriched. In our study, the four sequential stages of enrichment provide incredible value, 
clearly demonstrating cytoplasmic contaminants, and removing variation associated 
with looking at just two samples. It also further emphasizes how carefully one must 
consider the complications of aligning sequencing data given the presence of NUMTs. 
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Experimental Procedures 
Mitochondrial Isolation 
One three-month-old C57BL/6 male mouse was euthanized with CO2 and the liver was 
quickly rinsed in ice-cold Buffer A (220 mM mannitol, 70 mM sucrose, 5mM HEPES, 1 
mM EGTA, pH 7.4 + cOmplete, EDTA-free Protease Inhibitor Cocktail (Roche)). The 
liver was minced and rinsed in Buffer A containing 1 mg/ml BSA, and homogenized with 
two strokes of a dounce homogenizer. Whole tissue lysate sample was set aside at this 
point. Crude mitochondria were isolated by differential centrifugation at 1000g for 10 min 
at 4⁰C, followed by centrifugation of the supernatant at 8000g for 10 min at 4⁰C. A 
portion of the pellet was saved as the crude mitochondrial sample. The remainder was 
resuspended in 300 µl Buffer A containing no EGTA and supplemented with 1mM 
CaCl2, BSA 100 µg/ml, and 4000 gel units Micrococcal Nuclease (NEB M0247S). The 
remainder was separated on a percoll gradient spun at 20000 rpm for 45 min. in an 
SW60 rotor. Percoll-purified mitochondria were removed from the 26%-56% interface. 
All mitochondrial samples were spun for 1.5 min at 10000g and the pellet was lysed with 
600 ul lysis/binding buffer (MirVana RNA isolation kit). RNA was isolated according to 
manufacturers instructions. 
DNase treatment 
RNA was treated with 2U TURBO DNase (Ambion) in a 50ul reaction at 37⁰C for 30 
min., then an additional 2U was added and incubated for another 30 min. at 37⁰C. 
DNase was inactivated with .1 volumes DNase Inactivation Reagent (Ambion) and 
incubated five min. at room temperature. After centrifugation at 10000g for 1.5 min, the 
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RNA was transferred into a fresh tube and ethanol precipitated with .1 volumes 3M 
NaOAc, 1 µl glycogen and 2.5 volumes cold 100% EtOH. The sample was placed at -
80⁰C for at least 0.5 hr, then centrifuged at full speed (>13,000 x g) at 4⁰C for 20 min. 
The pellet was twice washed with 500 µl 70% ethanol and centrifuged at full speed 
(>13,000 x g) at 4⁰C for 10 min. The pellet was air dried and resuspended in water. 
Large RNA-seq library preparation 
RNAs larger than 160 bp were isolated on a 10% TBE urea gel. Strand-specific RNA-
seq library preparation was as described (Yassour et al., 2010). Library was sequenced 
with 76 bp paired end reads on an Illumina GAII instrument. 
tRNA-sized RNA-seq library preparation 
RNAs from 50-100 bp in size were isolated on a 10% TBE urea gel. We dissolved 200 
ng of each RNA sample in 25 µl H2O and denatured at 75⁰C for 4 min. then quickly 
chilled on ice. We added a 25 µl poly (A) tailing reaction mix that contained 25 U Poly(A) 
polymerase (New England Biolabs), 50 nmol ATP, 25 U of SUPERaseIn RNase 
Inhibitor (Ambion), 1x Poly(A) Polymerase Reaction Buffer, and incubated at 37⁰C for 15 
min., adding 312.5 nmol EDTA to stop the reaction. We cleaned up the reaction using 
Phenol:Chloroform:IsoAmyl Alcohol (PCIA) extraction and followed by ethanol 
precipitation. We denatured poly(A)-tailed RNA together with 50 pmol of 
5’-GGCATTCCTGCTGAACCGCTCTTCCGATCTTTTTTTTTTTTTTTTTTTTTVN-3’ in 
10.4 µl H2O at 75⁰C for 4 min., then quickly chilled on ice. We added 9.6 µl first-strand 
cDNA synthesis mix that contained 20 U Superscript III (Invitrogen), 200 nmol DTT, 40 
nmol dNTP (New England Biolabs), 20 U SUPERaseIn RNase Inhibitor and 1x first-
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strand cDNA synthesis buffer, incubated immediately at 55⁰C for 15 min. We removed 
RNA by adding 10 µl 1M NaOH and heating at 70⁰C for 30 min. We then added 10 µl 
1M HCl to neutralize the reaction. We cleaned up the reaction using PCIA extraction 
and followed by ethanol precipitation with only 0.067x volume of 3M NaOAC. We 
removed the leftover reverse transcripion oligonucleotides by gel separation on a 10% 
TBE urea gel. We denatured the first-strand cDNA together with 1 nmol tagged random 
primer 5’- CTCTTTCCCTACACGACGCTCTTCCGATCTNNNNNN-3’ in 35 µl H2O at 
75⁰C for 4 min. then quickly chilled on ice. We added 65 µl second-strand cDNA 
synthesis mix that contains 20 U Large (Klenow) fragment (New England Biolabs), 50 
nmol dNTP and 1x NEB Buffer 2, incubated at room temperature for 10 min. followed by 
37⁰C for 30 min. We cleaned up this reaction by using 1.8x AMPure XP SPRI beads 
(Beckman Coulter Genomics). We used 25% double stranded cDNA in the final 50 µl 
PCR reaction that contained 1x Phusion® High-Fidelity PCR Master Mix with GC Buffer 
(New England Biolabs), 50 µmol Betaine (USB), and 12.5 pmol each of forward primer  
5’- AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCT-3’ and 
reverse primer  
5’- CAAGCAGAAGACGGCATACGAGATCGGTCTCGGCATTCCTGCTGAACCGC-3’. 
We performed the PCR reaction at 98⁰C for 30 seconds, 5 cycles of 10 seconds at 98⁰C, 
30 seconds at 50⁰C and 30 seconds at 72⁰C, followed by 7 cycles of 10 seconds at 
98⁰C, 30 seconds at 65⁰C and 30 seconds at 72⁰C, then 5 min. at 72⁰C. We gel size 
selected a PCR product ranging from 160 to 240 bp for sequencing. The library was 
sequenced on Illumina GAII with 36b PE reads. 
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Sequence alignment 
Unless otherwise specified the sequencing libraries were aligned with Tophat, a gapped 
align tool for RNA-seq (Trapnell et al., 2009). For visualization of coverage, igvtools was 
used to compute coverage using a 5 bp window (Thorvaldsdóttir et al., 2013). 
Quantitation of transcripts with Cufflinks 
We used the Cufflinks command to quantitate transcripts without annotation within each 
library based on the mm9 genome, then used the cuffcompare and cuffdiff commands to 
compare abundance of transcripts across samples (Trapnell et al., 2010).  
Quantitation of transcripts with Trinity 
We used the Trinity package to quantitate transcripts without any genome reference in 
our 76 bp dataset as described (Grabherr et al., 2011; Haas et al., 2013). 
Quantitation of targeted transcripts from the tRNA-sized library 
We obtained tRNA annotations for the mouse genome (mm9) from the Genomic tRNA 
Database (http://lowelab.ucsc.edu/GtRNAdb/) (Chan and Lowe, 2009) and combined 
this list with sequences of mtDNA-encoded tRNAs extracted from the mouse 
mitochondrial chromosome Genbank file (NC_005089). We ran Bowtie against this file 
using the --best --a --strata -m 1 flags to require only one mismatch and only report the 
best match or matches in the same strata. This was also repeated for the 5S rRNA 
sequence (NR_030686.1). For the second method, we used the Tophat alignments 
described and the Scripture score function (Guttman et al., 2010) to count the number of 
reads mapping to the repeatmasker annotated regions (http://repeatmasker.org). 
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Quantitation of RNase MRP and RNase P RNA in large RNA-seq library  
We ran Bowtie against this a file containing the RNase MRP RNA (NR_001460.1) 
RNase P RNA (NR_002142.2) sequences using the --best --a --strata -m 1 flags to 
require one mismatch and only report the best match or matches in the same strata. 
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Chapter 5 
Conclusion 
 
 In this dissertation, I explore the intersection of genomics, biochemistry, and 
medicine to expand our knowledge of mitochondrial RNA biology. In Chapter 2, I 
discuss the application of MitoString, a tool for mitochondrial RNA profiling, to broad-
scale RNAi knockdown of mitochondrial proteins. This leads to the identification of the 
previously uncharacterized protein, FASTKD4, as a regulator of mitochondrial RNAs, 
which I validate in-depth. In Chapter 3, I apply MitoString to a fibroblast model of 
suspected mitochondrial disease, in which MitoExome sequencing had prioritized 
variants of unknown significance. This case highlights the value of an appropriate model 
to provide insight in unknown diseases. In Chapter 4, I use an unbiased approach to 
characterize RNAs residing within the mitochondria. Collectively, these studies expand 
our knowledge of mitochondrial RNA biology and pose questions for future research. 
 As illustrated by our case of suspected mitochondrial disease in Chapter 3, an 
understanding of the function of mitochondrial proteins is essential to understanding 
pathogenesis of mitochondrial disorders. In Chapter 2 we knock down over 100 
mitochondrial-localized proteins with predicted RNA-binding domains and survey the 
effect on mitochondrial RNA abundance and processing. This atlas is a powerful 
resource for scientists investigating the function of these proteins in health and disease. 
Further, I have investigated the role of FASTKD4, a new regulator of mitochondrial 
RNAs. Reconciling that depletion of FASTKD4 affects only a subset of mRNAs while 
binding all of them, likely involves the identification of a new player in mitochondrial RNA 
metabolism, which future studies should investigate. How the many different regulators 
of mitochondrial RNA, especially LRPPRC/SLIRP, interact with FASTKD4 is also an 
open question. Future studies may determine whether FASTKD4 associates with the 
LRPPRC/SLIRP complex, mitochondrial ribosomes, or acts independently on RNA 
transcripts. How FASTKD4 interacts with the degradation machinery is still unclear, as 
is the exact mechanism and specificity of the degradation machinery itself, including 
SUPV3L1. 
 Understanding the effect of specific variants on disease pathogenesis is currently 
one of the major challenges of human genetics. Chakravarti et al. suggest proof is 
necessary at two levels to indict a particular variant in a complex genetic case: the 
variant must be found necessary for the phenotype in a tested model system and the 
model system phenotype must be considered a valid stand-in for the disease itself. We 
sought the first level of proof with fibroblasts derived from the human patient. As we 
suspected variants in the gene SUPV3L1, and disruption of this gene is known to cause 
elevation in noncoding light strand transcripts, we tested this phenotype with our 
MitoString assay. We found no phenotype suggestive of a SUPV3L1 defect in the 
patient fibroblasts, thus our model provided no evidence that the mutations were 
pathogenic. It is possible that our model was not relevant to the disease, but patient 
fibroblasts have been considered a useful model to validate pathogenic mutations in 
other mitochondrial patient cases (Calvo et al., 2010). Further, others subsequently 
found mutations in a non-mitochondrial gene (Enns et al., 2014). Our study provides an 
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example of determining the functional significance of variants of unknown function 
based on Koch’s postulates for Complex Human Disease (Chakravarti et al., 2013). 
 Both our investigation of RNA processing proteins in Chapter 2 and our 
suspected mitochondrial disease patient in Chapter 3 highlight the power and limitations 
of using MitoCarta for prioritized screening. In Chapter 2, we identified a novel protein 
involved in mitochondrial RNA regulation, but we also missed a chance to understand 
some proteins that were not in MitoCarta at the start of the study, but were subsequently 
found to be mitochondrial-localized and involved in RNA processing. However, focusing 
on a larger pool of candidates would not have been experimentally feasible with 
MitoString, and would have resulted in less interesting data for a larger pool of 
candidates. In our case, with our smaller set of candidates, we obtained rich data on 
mitochondrial RNA transcript abundance for each knockdown. In the patient case, we 
obtained the MitoExome of the individual on the hypothesis that the patient suffered 
from mitochondrial disease. In the end, this was not the case, thus our MitoExome 
sequencing did not predict the pathogenic variant. For many other cases, this approach 
was successful (Lieber et al., 2013). However, this particular case highlights the 
complexity of diagnosing mitochondrial disorders, as non-mitochondrial disorders may 
present as mitochondrial. Future exome-sequencing studies on mitochondrial patients 
would be wise to cover the full genome, as plummeting sequencing costs make that 
more feasible. 
 Our survey of mitochondrial RNA transcripts in Chapter 4 highlights both the 
value and limitations of unbiased genome-wide approaches. We performed RNA 
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sequencing on mouse liver homogenate and sequentially enriched mitochondrial 
samples to identify whether any nuclear-encoded RNAs were imported into 
mitochondria. We found that even the one thoroughly characterized case, 5S rRNA, was 
difficult to identify in our dataset without specifically looking for it. 5S rRNA is extremely 
abundant within the cell, so mitochondrial fractions contained 40% of the 5S rRNA found 
in the whole tissue lysate, yet in vitro studies have biochemically characterized its import 
into the mitochondrion. For 5S rRNA we do note persistence across our three purified 
mitochondrial samples that is absent for measured nuclear tRNAs, which continue to be 
depleted with each enrichment step. However, absent prior information, I am not certain 
that our genome-wide study or a similar study in human cells would have identified 5S 
rRNA as imported. Further, the lowly expressed MRP and RNase P RNAs were not well 
detected in our dataset, although deeper sequencing may solve this issue. Yet, for the 
import case, careful biochemical characterization may be more definitive than genome-
wide studies. 
 Biochemical studies have also identified tRNA-Gln as imported into the 
mitochondria, but absent the level of proof presented in the 5S rRNA case, there may 
be reason to be skeptical (Rubio et al., 2008). We find no evidence for import of nuclear 
tRNAs, and note that there are annotated tRNAs within NUMTs in the human nuclear 
genome that may confound studies on this point. However, as there are numerous 
biological and technical discrepancies between our study and the others, there are 
many possible reasons for our differing findings, as detailed in Chapter 4. 
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 Overall, this dissertation uses a diverse set of approaches to characterize 
aspects of mitochondrial RNA biology. I have introduced a new regulator of 
mitochondrial RNAs, FASTKD4, and further characterized established regulators with 
MitoString. I also applied MitoString to fibroblasts derived from a suspected 
mitochondrial disease patient, providing an example of the power of molecular 
approaches to provide guidance in difficult genetic cases. Further, I have described an 
unbiased approach to characterize the mitochondrial-localized transcriptome of mouse 
liver, which may be in conflict with previous findings in humans and rat (Mercer et al., 
2011; Rubio et al., 2008). Together, these findings contribute to our understanding of 
the essential mitochondrial RNAs that produce energy-generating OXPHOS subunits 
and raise questions to be answered by future studies. 
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Appendix A 
Supplemental Information for Chapter 2 
 
 
  
 
Figure 2-S1: Reproducibility of the MitoString assay, Related to Figure 2-1 
(A) Normalized nCounter counts for all probes are plotted for one shGFP replicate vs. another. 
Histogram of CV values for individual probes targeting mtDNA-encoded mRNAs (B) and 
precursor (C). (D) Histogram of CV values for individual probes targeting nuclear genes. (E) 
Histogram of percent expression remaining of a given silenced gene within the dataset. (F) 
Principal component analysis of expression data matrix displayed in Figure 2-2.  PC1 and PC2 
account for 38% and 19% of the variance respectively and PC2 separates the probes based on 
the displayed categories (light or heavy strand, junction or mRNA). 
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Figure 2-S2: Perturbations that increase mtRNA abundance, Related to Figure 2-2 
MitoString measurements of RNA expression in uninfected cells and PGC1alpha 
overexpressing cells for mt-mRNAs (A), mt-RNA junction and non-coding probes (B) and for 
nuclear mitochondrial-localized genes (C). (D) MitoString quantitation for mtDNA probes under 
MTG1 silencing by three distinct hairpins (% expression remaining of MTG1 is denoted) E) 
MitoString quantitation for mtDNA probes under C21orf33 silencing. (F) The Pearson correlation 
score of the mouse homolog of human C21orf33 (D10Jhu81e) with the expression of all genes, 
genes in MitoCarta, and OXPHOS subunits across samples in the GNF Mouse GeneAtlas v3.  
Here, barplots represent the mean of duplicates, with the error bars representing the range. 
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Figure 2-S3: Measuring RNase Z activity at measured tRNA_mRNA junctions and 
assessing the ATP6/8_COX3 junction, Related to Figure 2-3 
(A-F) The probe count for each knockdown hairpin was plotted for each set of neighboring 
probes. Genes that disproportionally affect one probe are found offset from the distribution and 
labeled (Supplemental experimental procedures).  
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Supplemental data tables 
(Excel spreadsheets can be found in the accompanying file or online in supplemental 
information for Wolf and Mootha, 2014 Cell Reports) 
 
Table 2-S1: shRNA hairpins used, Related to Figure 2-2 (see attached Excel sheet) 
 
Table 2-S2: Knockdown efficiency, Related to Figure 2-2  (see attached Excel 
sheet) 
 
Table 2-S3: Raw matrix of nCounter counts for shRNA knockdown samples, 
Related to Figure 2-2  (See attached Excel sheet) 
Samples identified by TRCNXXXXXXXXXX, identified in Table 2-S1. 
 
Table 2-S4: Processed nCounter data, Related to Figure 2-2  (see attached Excel 
sheet) 
Raw data was normalized by the geometric mean of endogenous controls and divided 
by the mean of shGFP replicates (TRCN0000072179).  Duplicates were averaged and 
the log2 was taken of all samples. 
 
Table 2-S5: Mitochondrial disease genes targeted in the current study, Related to 
Figure 2-2 
 
Gene 
Symbol 
Disease (OMIM ID) Proposed 
Pathogenesis 
Previous 
result 
Current study References 
AFG3L2 spinocerebellar 
ataxia type 28 
(610246), spastic 
ataxia-5 (604581) 
translation 
defect 
unchanged 
(northern 
blot, mice) 
slight decrease 
some transcripts 
Almajan et al., 
2012 
ELAC2 Combined oxidative 
phosphorylation 
deficiency 17 
(615440) 
defect in RNA 
processing 
precursor 
stabilized 
precursor 
stabilized 
Haack et al., 2013  
FASTKD2 cytochrome c 
oxidase deficiency 
(220110) 
apoptosis defect – decrease heavy 
strand mt-mRNAs 
Ghezzi et al., 
2008 
GFM1 combined OXPHOS 
deficiency (609060) 
translation 
defect 
- negligible effect Smits et al., 2011 
LRPPRC Leigh syndrome 
(220111) 
decreased mt-
mRNA levels 
decreased 
mt-mRNA 
levels 
(qPCR, 
northern 
blot) 
decrease all 
heavy strand 
RNAs 
Sasarman et al., 
2010; Gohil et al., 
2010 
MTO1 hypertrophic 
cardiomyopathy and 
lactic acidosis 
(614702) 
translation 
defect 
decreased 
mt-mRNA 
levels 
(northern 
blot, yeast) 
slight decrease 
heavy strand mt-
mRNAs 
Ghezzi et al., 
2012; Wang et al., 
2009 
MTPAP spastic ataxia 
(613672) 
polyadenylation 
defect 
conflicting 
results 
(qPCR) 
decrease some 
mt-mRNAs 
Crosby et al., 
2010; Nagao et 
al., 2008; Piechota 
et al., 2006 
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Table 2-S5 (continued) 
 
Gene 
Symbol 
Disease (OMIM ID) Proposed 
Pathogenesis 
Previous 
result 
Current study References 
PNPT1 combined OXPHOS 
deficiency (614932); 
hereditary hearing 
loss (614934) 
translation 
defect  
transcripts 
distinctly 
regulated 
(northern 
blot) 
CYTB and ND2 
increased, some 
junctions 
decreased 
Vedrenne et al., 
2012 ; von Ameln 
et al., 2012; 
Borowski et al., 
2013 
PUS1 MLASA (600462) translation 
defect 
- strong 1-hairpin 
depletion of 
ATP6/8,COX3, 
and CYTB; 
junction probes 
increased 
Fernandez-Vizarra 
et al., 2007; 
Patton et al., 2005 
TACO1 Leigh syndrome 
(256000) 
translation 
defect 
- slight light strand 
depletion 
Weraarpachai et 
al., 2009 
TIMM8A deafness–dystonia 
(Mohr-Tranebjaerg) 
syndrome (304700) 
protein 
translocation 
- slight mt-mRNA 
depletion 
Aguirre et al., 
2006 
TRMU acute reversible 
infantile liver failure 
(613070) 
translation 
defect 
- negligible effect Zeharia et al., 
2009 
TUFM combined OXPHOS 
deficiency (610678) 
translation 
defect 
- ND5 depletion Valente et al., 
2007 
 
Table 2-S6: Antibodies, Related to Experimental Procedures 
Source Catalogue Type Antigen Western Dilution 
Abcam ab99317 rabbit polyclonal FASTKD4 1:10000  
Cell Signaling 2128 rabbit polyclonal Tubulin 1:2000  
Abcam  ab291 mouse GFP 1:50000 
BD Bioscience 611980 mouse monoclonal OXAL1 1:2500  
Mitosciences MS405 mouse monoclonal COX2 1:10000  
Mitosciences MSA04 mouse monoclonal Cyclophilin D 1:10000  
Mitosciences MSA06 mouse monoclonal Cytochrome C 1:10000  
Santa Cruz SC-373752 mouse FASTKD4 1:1000 
Sigma SAB2700419 rabbit LRPPRC 1:1000 
Abcam ab114993 rabbit TFAM 1:1000 
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Table 2-S7: Primers, Related to Experimental Procedures 
 
Supplemental experimental procedures 
shRNA selection 
The three best hairpins per gene were selected for screening based on qPCR 
knockdown validation data from the Broad RNAi platform, where available, or 
computational predictions using RuleSet8 (The RNAi Consortium).  
Screen 
15000 WI-38 cells/well were seeded in 96-well format and infected after 24-hours with 
10 ul of virus prepared by the Broad RNAi consortium in media containing 8ug/ml 
polybrene. Plates were spun at 800g for 15 minutes. 24 hours, 72 hours, and 96 hours 
post-infection the media was refreshed with media containing 2ug/ml puromycin. 6 days 
post-infection the cells were lysed with RLT buffer (Invitrogen) and β-Mercaptoethanol 
(100:1) and frozen. RLT lysates were hybridized overnight at 65C with a custom 
MitoString codeset from NanoString technologies, and processed with the nCounter 
Name Description Sequence 
FASTKD4_725_F Quickchange to 
generate FASTKD4 
resistant to hairpin 
TRCN0000157725 
CCGCTGGCGCATGCGCAAACTGAAGTATAAGCA
CCTGGC 
FASTKD4_725_R Quickchange to 
generate FASTKD4 
resistant to hairpin 
TRCN0000157725 
GCCAGGTGCTTATACTTCAGTTTGCGCATGCGCC
AGCGG 
U6 For FASTKD4ko 
generation 
GCCTCTAGAGGTACCTGAGGGCCTATTTCCCATG
ATTCC 
sgRNA For FASTKD4ko 
generation 
ACCTCTAGAAAAAAAGCACCGACTCGGTGCCACT
TTTTCAAGTTGATAACGGACTAGCCTTATTTTAAC
TTGCTATTTCTAGCTCTAAAACCTAATGAACCGCC
TGGAAGACGGTGTTTCGTCCTTTCCACAAG 
CRISPR_L For FASTKD4ko 
generation 
CAAGATCGTGCTGTGATGGG 
CRISPR_R For FASTKD4ko 
generation 
GGTTACAGACACCAAGCGTC 
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robotic system per manufacturer’s instructions (Geiss et al., 2008). nCounter counts are 
presented as either raw counts or normalized counts. Normalized counts are raw counts 
divided by the geometric mean of endogenous controls (ABCF1, ACTB, CLTC, HPRT1, 
TUBB) after background subtraction, presented as log2(normalized counts/shGFP), 
where shGFP is the mean of all infections with hairpin TRCN0000072179. Samples that 
were either too dense or too sparse were discarded from further analysis. Lowly 
expressing probes were also discarded. In raw count x-y scatterplots, points were 
labeled if they were categorized into the smaller of two linear regression groups in a 
mixture model explaining all data (Leisch, 2004). 
FLAG-tagged protein expression 
The V5 tag of the plex-TRC-983 Gateway destination vector (Broad RNAi Consortium) 
was replaced with a FLAG tag via PCR (Accuprime), restriction digestion (BstZ171, 
NheI, New England Biolabs), and ligation (Quick Ligase, New England Biolabs) to 
create plexFLAG. Mitochondrial-targeted eGFP was amplified via PCR to append BP 
sites and introduced into pDONR221 via Gateway BP reaction (Invitrogen). pDONR223-
FASTKD4 was obtained from a previously described cDNA library (Pagliarini et al., 
2008) and the RNAi site and RAP domain mutagenized via QuikChange mutagenesis 
(Agilent) using the primers described in Table S7. FASTKD4mut-FLAG contains the 
following amino acid changes: Y616A, L617A, K618A, K620A (NP_004740). All cDNAs 
were cloned into plexFLAG via LR reaction (Invitrogen). 
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Co-expression analysis 
Using the GNF Mouse GeneAtlas v3 (Lattin et al., 2008), which quantifies the RNA 
expression of over 17,000 genes across 91 C57BL/6 mouse tissues or cell types using 
Affymetrix MOE430_2 microarrays, we calculated the Pearson correlation coefficient for 
each gene with D10Jhu81e, the mouse homolog of c21orf33 across all samples.  We 
plotted this Pearson coefficient for all genes, MitoCarta genes (Pagliarini et al., 2008), 
and OXPHOS genes (Baughman et al., 2009).  
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